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ABSTRACT 
 
MULTIPLE ROLES OF BRD4 IN THE HUMAN  
PAPILLOMAVIRUS LIFE CYCLE 
Christine M. Helfer 
Jianxin You 
While human papillomavirus (HPV) vaccines protect against acquiring new 
infections, there is currently no antiviral treatment for eradicating persistent HPV 
infections.  In this study, I demonstrated that the cellular chromatin binding protein, 
Brd4, in association with HPV E2 protein, is important for multiple HPV functions 
including replication, maintenance of viral genomes, and regulation of viral gene 
transcription.  These studies suggest that the E2-Brd4 complex could be an effective 
target to disrupt the HPV life cycle.  Using bimolecular fluorescence complementation, 
we demonstrate that E2 from high-risk HPV16 interacts with Brd4 on cellular 
chromosomes throughout mitosis while the BET bromodomain inhibitor, JQ1(+), 
dissociates Brd4-E2 complexes from mitotic chromosomes.  These results suggest that 
Brd4 is important for tethering HPV16 E2 to mitotic chromosomes for stable viral 
genome maintenance and that abrogating Brd4’s chromatin association might disrupt 
stable HPV genome maintenance.  I also found that JQ1(+) treatment of cells stably 
maintaining papillomavirus genomes reduces viral mRNA levels, demonstrating that 
HPV association with cellular chromatin through Brd4 is essential for HPV transcription 
and further supporting the importance of Brd4 for the HPV life cycle.  My work also 
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identified a novel role of Brd4 in HPV16 DNA replication.  Immunofluorescence 
analyses show Brd4 is recruited to nuclear foci actively replicating HPV16 genomes.  
Replication assays further confirm that Brd4 is essential for HPV16 genome replication.  
Interestingly, JQ1(+) treatment stimulates viral genome replication.  Since HPV genome 
amplification is normally limited to upper epithelial layers, we predict premature 
stimulation of viral DNA amplification induced by JQ1(+) in basal epithelial cells might 
activate host immune responses to clear HPV infection.  Finally, this work identified a 
specific function of Brd4 in papillomavirus transcription activation.  Using ChIP analysis 
and an E2-responsive luciferase assay, we show Brd4 actively recruits P-TEFb to 
papillomavirus genomes to support E2 transactivation function.  Together, this study 
uncovers two novel functions of Brd4 in the HPV life cycle, improving our understanding 
of this complex virus-host relationship.  Furthermore, we identify the E2-Brd4 complex 
as a promising antiviral target for eliminating HPV persistent infection. 
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CHAPTER 1:  Introduction 
	  
1.1:  The Human Papillomavirus Life Cycle and HPV-Associated Cancers 
	  
1.1.1:  The Papillomavirus Life Cycle 
	  
 Papillomaviruses are small, non-enveloped, DNA viruses that infect dividing 
basal cells of stratified squamous and cutaneous epithelia.  HPV is the most common 
sexually transmitted virus infection and over 150 different types of HPVs have been 
identified to date (99).  The most common HPV subtypes associated with cancer include 
HPV type 16, 18, and 31, which are termed “high-risk” HPVs (HR-HPV) while the 
majority of HPV types are considered “low-risk” (LR-HPV) since they are not usually 
associated with human cancers (42, 43, 142, 185, 205).  LR-HPV types are commonly 
associated with benign anogenital warts and warts of the hands and feet (43). 
Viral entry into cells occurs when the virus gains access to the basal epithelial 
layer through microwounds (42).  The viral capsids initially bind to the basement 
membrane and infect basal keratinocytes present in the wound (Fig. 1.1, (97, 236)).  After 
entry and uncoating, the virus establishes early infection in the nucleus and replicates its 
genomes to about 100 genome copies per cell (42).   
2 
	  
 
Figure. 1.1.  Model of the productive HPV life cycle (adapted from Springer, Cancer 
Associated Viruses, 2012, 19/Human Papillomaviruses and Cancer, You J. and Wells S., 
Fig. 19.2, DOI 10.1007/978-1-4614-0016-5_19, © Springer Science and Business Media 
(228)).   
 Papillomaviruses have a circular double-stranded DNA genome, which is termed 
an episome.  The viral genome is about 8000 base pairs in length and can be divided into 
three regions (Fig. 1.2).  The long control region (LCR) consists of the origin of 
replication, transcriptional enhancers, and promoters.  The early region encodes viral 
proteins expressed early during infection from early promoters (PE) including the 
oncoproteins, E6 and E7, the replication proteins, E1and E2, and the accessory proteins, 
E4 and E5.  The late region encodes the capsid proteins, L1 and L2, which are 
exclusively expressed from the late promoter (PL) during late infection (92).  Expression 
of the viral proteins is tightly regulated and is linked to the differentiation program of the 
infected epithelial cell (136).  During early infection, E1 and E2 are expressed at low 
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level to replicate the viral genome once per cell cycle.  This is the maintenance phase of 
the HPV life cycle in which the virus establishes a stable, persistent infection in 
replicating basal cells.  Since both viral protein expression and viral genome replication 
are maintained at minimum level, the virus is able to evade the host immune system so 
that infection can persist in basal epithelial cells for many months, or in rare cases, years 
or decades (21).    
 
Figure 1.2.  Organization of the HPV16 genome (adapted from Doorbar et al., 2012 
(43)). 
 Normal human squamous epithelia grow as stratified layers where only cells in 
the basal layer are able to divide (210).  After basal cell division, one daughter cell 
becomes a new basal cell while the other migrates up the epithelial layer and undergoes 
differentiation.  These differentiated cells normally withdraw from the cell cycle and 
begin keratin synthesis and nuclear breakdown (210).  However, during HPV infection, 
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the viral oncoproteins, E6 and E7, prevent the normal cell cycle exit of the differentiated 
cells to set up a cellular environment conducive for viral genome amplification and virion 
production (52, 62).  E7 functions to drive infected cells into S phase by binding to 
phosphorylated retinoblastoma (pRb) proteins and inhibiting their interaction with E2F 
transcription factors (141).  E7 also associates with other proteins involved in cell 
proliferation including cyclin-dependent kinase inhibitors and histone deacetylases (117, 
141).  E6, on the other hand, primarily functions to inactivate p53 to block growth arrest 
and apoptosis in response to the cell cycle changes mediated by E7 (79).  Furthermore, 
E6 has several other oncogenic functions including activating telomerase, altering 
transcription, reducing immune recognition, and disrupting cell adhesion and 
differentiation (79). 
Differentiation of infected epithelial cells triggers activation of the viral late 
promoter, which leads to high expression of E1 and E2 (43).  These elevated levels of the 
viral replication proteins initiate the genome amplification phase of the papillomavirus 
life cycle in which viral genomes amplify to thousands of copies per cell (Fig. 1.1).  Late 
after the onset of genome amplification, the viral capsid proteins are expressed and 
virions are assembled.  Virions are shed from the top layer of the epithelia with 
desquamated cells in the absence of cell lysis or necrosis, thus avoiding inflammation 
while contributing to virus persistence (73).   
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1.1.2:  HPV-Associated Cancers 
 Infection by HR-HPVs is associated with cervical cancer, which is the second 
most prevalent cancer in women worldwide and kills roughly 288,000 women annually 
(142, 185, 205).  In addition, HR-HPV is the causative agent in many anal cancer cases 
(236).  In recent years, it has become increasingly apparent that HPV is also an important 
cause of some oropharyngeal cancers (236).   
Persistent HR-HPV infection over long periods is the single most important risk 
factor for the development of HPV-associated cancer (189, 214).  Furthermore, 
integration of the HPV genome into the host chromosome is found in most cervical 
cancer cases, suggesting that this is a critical event in cancer development (29, 89).  It is 
thought that extended periods of manipulating cell proliferation and cell cycle 
checkpoints by the HPV oncoproteins gradually induces genomic instabilities, which 
allow the viral genome to become integrated into the host chromosome (47).  
Intriguingly, several studies have indicated a preference for HPV integration at common 
fragile sites in the host genome and have suggested that changes in the expression of 
cellular genes near the integration site might participate in cancer development (31, 123, 
195, 196).  When these integrated viral genomes were analyzed, it was discovered that 
most integrations disrupt the E2 gene so that it is no longer expressed (166).  This is 
important because E2 negatively regulates E6 and E7 expression and derepression of 
these viral oncogenes is required for malignant progression (45, 72, 90).  However, cells 
immortalized with HR-HPV are non-tumorigenic at low passage numbers.  They require 
extended growth or expression of additional oncoproteins such as ras or fos to become 
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tumorigenic, suggesting that HPV infection is necessary but not sufficient for cancer 
development (8, 48, 156).  Indeed, it was established that accumulation of secondary 
mutations in the cellular genome over several years of HPV persistent infection is 
required for cell transformation to cancer (235). 
HPV-associated cancers are composed of cells that have lost the ability to 
differentiate and can no longer support the complete viral life cycle.  In addition, the viral 
genomes in these cancer cells are usually integrated so they are unable to replicate.  
Together, this means that cancer cells do not produce HPV virions and are therefore a 
dead end for the virus.  Since this does not benefit the virus, an interesting question to 
ponder is why HR-HPVs cause cancer.  One possibility is that development to cancer 
could simply be a mistaken side effect of inactivating pRb and p53 surveillance 
pathways, which are necessary for HPV replication. 
1.1.3:  Current Treatments for HPV Infection 
	   Infection with HPV is very common and is normally identified and cleared by the 
host immune system before cancer can develop (76, 88).  Still, about 450,000 new cases 
of cervical cancer are diagnosed each year (155).  The wide utilization of the 
Papanicolaou (Pap) smear in the developed world has enabled early detection of cellular 
abnormalities associated with HPV infection and has resulted in an 80% reduction in the 
number of cervical cancer cases in the US (182).  Furthermore, there are now two 
commercially available prophylactic HPV virus-like particle vaccines that protect against 
HPV types 16 and 18 (Cervarix) and HPV types 6, 11, 16, and 18 (Gardasil). While these 
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vaccines will likely further reduce the incidence of HPV-associated diseases in the 
developed world, these diseases will likely remain prevalent in developing countries 
where the Pap smear and HPV vaccines are not as widely available.  In addition, the HPV 
vaccines do not protect against every high-risk HPV type and are ineffective at treating 
established infections so there is still a strong need for antiviral drugs to eliminate 
ongoing HPV infections (9, 198).   
1.2:  E2 Functions in the HPV Life Cycle 
1.2.1:  E2 Domain Structure  
 E2 is the major regulatory protein encoded by all papillomaviruses.  The E2 
protein consists of an N-terminal transactivation domain linked to a DNA 
binding/dimerization domain.  The two domains are connected by a flexible “hinge” 
linker sequence.  All papillomaviruses have the potential to also express alternatively 
spliced short E2 variants that lack most of the transactivation domain.  These short forms 
usually function as inhibitors of full-length E2 by competing for E2 binding sequences 
(114, 135). 
Through a conserved DNA binding domain, E2 proteins bind specific consensus 
motifs located in the viral LCR (Fig. 1.1, (6, 71, 127, 139)).   In the alpha subgroup of 
papillomaviruses, which includes the high-risk HPV subtypes, there are four E2 binding 
sites in the LCR important for regulating viral transcription, replication, and episome 
maintenance.  Interestingly, despite no sequence similarity, the E2 DNA binding domain 
has significant structural similarity with that of the EBV EBNA1 protein (20).  
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The amino-terminal 200 amino acids of E2 form the conserved transactivation 
domain.  This region is essential for both transcription activation and repression of viral 
genes as well as for viral replication (126, 133).  The crystal structure of the E2 
transactivation domain for several PVs including HPV16 and HPV18 has been solved (7, 
70).  In all PVs analyzed, the transactivation domain forms a cashew shaped structure 
with the amino acids important for transcription located on the convex face while the 
amino acids important for replication are located on the concave face of the domain. 
The E2 DNA binding domain also contains a dimerization region.  E2 proteins 
form stable dimers upon translation (126, 134, 140).  These E2 dimers can be 
homodimers consisting of two full-length or short E2 isoforms or they can be a 
heterodimer of a full-length E2 and a short E2.  The heterodimers have been shown to 
support viral replication and transcription but are unable to tether the viral genome to host 
chromosomes for episome partitioning (102-104). 
The E2 hinge region is highly variable between PV subtypes in both sequence and 
length and is thought to be an unstructured, flexible linker between the transactivation 
and DNA binding domains (63, 67, 126).  The hinge is not required for E2’s replication 
and transcription functions but serves as a necessary spacer to avoid steric hindrance 
between the two domains (213).  Notably, the hinge region contains several 
phosphorylation sites that are important for E2 auxiliary functions such as protein 
stability and subcellular localization (125, 158, 177, 178, 233).    
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1.2.2:  E2’s Role in Viral Genome Maintenance 
During the persistent phase of early papillomavirus infection, viral episomal 
genomes replicate once per cell cycle and are maintained in the nucleus at about 100 
copies per cell (65).  To ensure stable maintenance of these episomes between mitotic 
divisions, the virus must have a way to faithfully partition them to the nuclei of daughter 
cells.  Since papillomaviruses do not encode a centromere protein, they require another 
mechanism to ensure that the viral genomes remain within the nuclear envelope 
following nuclear membrane reassembly.  Otherwise, the viral genomes could be 
excluded from the nucleus after mitosis and lost through degradation or dilution.   
It is well established that E2 is the key viral factor required for stable maintenance 
of viral episomes in dividing cells through tethering the viral genomes to mitotic 
chromosomes (15, 159, 183).  The E2 DNA binding domain interacts with E2 binding 
sites in the viral LCR while the transactivation domain associates with a cellular factor 
bound to the mitotic chromosomes (3).  In the case of bovine papillomavirus, the cellular 
factor important for E2 association with mitotic chromosomes is bromodomain-
containing protein 4 (Brd4) (17, 224).  However, it is still unclear whether Brd4 also 
performs this function for other papillomavirus species.   
One study showed by immunofluorescence staining that E2 proteins from various 
HPV subtypes bind to different regions of mitotic chromosomes, suggesting that each PV 
subtype might target a different cellular factor on the chromosomes for episome tethering 
(147).  Another protein implicated in E2 tethering to mitotic chromosomes is the 
topoisomerase binding protein, TopBP1.  TopBP1 was shown to interact with HPV16 E2 
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and regulate the affinity of E2 for host chromatin (23, 40).  In addition, E2 and TopBP1 
colocalize on mitotic chromosomes during late stages of mitosis, supporting a role for 
this protein in E2-mediated episome tethering (40).  The DNA helicase, ChlR1, was also 
shown to interact with several PV E2s including HPV16 E2 (153).  Furthermore, using 
disruption of this interaction or knock-down of ChlR1, the E2-ChlR1 interaction was 
demonstrated to be necessary for E2 binding to mitotic chromosomes and for 
maintenance of episomes in dividing cells (153).  However, ChlR1 is thought to load E2 
and the associated viral genomes onto chromosomes only during S phase since E2 and 
ChlR1 were only found colocalized on chromosomes during early mitosis.  It is therefore 
possible that E2 proteins tether the viral genome to chromosomes through a complex 
process involving more than one cellular factor. 
1.2.3:  E2’s Role in Viral Genome Replication 
The PV origin of replication contains an E1 binding site, an A/T rich sequence, 
and one or more E2 binding sites (201).  E2 primarily functions in the initiation of viral 
genome replication by recruiting and loading the viral helicase, E1, onto the replication 
origin (171). Upon binding the origin, E1 assembles into double-hexamers and recruits 
the cellular replication machinery, while E2 is displaced from the origin for DNA 
replication to proceed (124, 175).   
Viral DNA replication takes place in nuclear foci and E2 is required for formation 
of these replication foci (193, 208).  Besides the viral and cellular replication factors, 
other cellular factors found within HPV replication foci include members of the ATM 
and ATR DNA damage pathway (55, 164, 170).  The cellular DNA damage response is 
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believed to facilitate HPV genome replication by recruiting cellular repair proteins to 
synthesize viral DNA (66, 164, 170).  E1 is the primary activator of the DNA damage 
response in cells because its helicase domain is able to bind non-specifically to cellular 
DNA and initiate inappropriate DNA unwinding, which causes damage throughout the 
cellular genome and a robust DNA damage response (55, 170).  E2 functions to direct E1 
binding specifically to the viral origin and with it, the DDR proteins are also localized to 
the viral replication foci, thereby reducing damage to the cellular genome caused by E1 
while facilitating HPV DNA replication (170).  
1.2.4:  E2’s Dual Functions in Viral Gene Transcription 
E2 is the principle transcriptional regulator of papillomaviruses and acts through 
binding specifically to E2 binding sites in the viral upstream regulatory region (URR) and 
recruiting cellular factors (187).  E2 can function as either an activator or repressor of 
viral transcription depending on the context of the E2 binding sites and the type of 
cellular factors that E2 recruits.  Cellular proteins recruited to the early promoter by E2 
include the transcription activators: CBP, p/CAF, BRCA1, Brm, and Brd4 as well as 
chromatin modifying proteins: SMCX, EP400, and TIP60 (96, 101, 109, 110, 184).  A 
number of studies suggest that E2 regulation of the early promoter is dose-dependent, 
activating transcription at low concentrations and repressing transcription at higher 
concentrations (60, 192, 194).  Steger et al. postulated that, at low concentrations, E2 
binds its high-affinity, distal sites in the LCR and recruits transcriptional activators to the 
early promoter.  As E2 levels increase, all four binding sites become occupied, which 
blocks the binding of transcriptional activators (192).  How this dose-dependent 
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transcription regulation functions during the HPV lifecycle is still unclear.  E2 levels are 
kept low during the maintenance phase of infection and increase to high levels during 
genome amplification in differentiated cells.  It is therefore possible that E2’s dual role in 
transcription regulation functions as a negative feedback loop in late infection where high 
E2 levels repress the viral oncogene expression to allow the cells to terminally 
differentiate, releasing virions into the environment with the sloughed off epithelia. 
1.3:  Brd4 Cellular Functions 
1.3.1:  Brd4 Structure and General Function 
Brd4 is a member of the bromodomain and extra terminal domain (BET) family, 
which in mammals includes Brd2, Brd3, Brd4, and BrdT.  These proteins all contain two 
tandem bromodomains (BDI and BDII) and an extra terminal (ET) domain but Brd4 is 
unique in that it also carries a long C-terminal domain (CTD) (Fig. 1.3, (50, 204)).  The 
BET family proteins are ubiquitously expressed in cells with the exception of BrdT, 
which is only found in the ovaries and testes (151, 180).  The double bromodomains of 
the BET family proteins are highly conserved and recognize acetylation marks at lysine 
14 on histone H3 and lysines 5, 12, and 16 on histone H4 (36, 204).  Until recently, only 
two isoforms of Brd4 were known to exist in cells.  The long isoform is predominant and 
is responsible for most of the functions attributed to Brd4 (215).  The Brd4 short isoform 
lacks the long C-terminal region after the ET domain and its function is not well 
understood, although it has been suggested to function as an inhibitor of full-length Brd4 
(215).  Notably, a recent publication identified a second short Brd4 isoform termed 
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“isoform B” (54).   Like the original short isoform, isoform B lacks the C-terminal region 
after the ET domain but in its place contains a divergent 75 amino acid segment (54).  
This novel isoform was shown to modulate chromatin structure to insulate DNA from 
DNA damage signaling (54).   
 
 
 
Figure. 1.3.  Organization of the domains of human Brd4.  BD: Bromodomain, ET: 
Extra-terminal domain, CTD: C-terminal domain.  The amino acid numbers are indicated 
above the image. 
 
1.3.2:  Brd4’s Functions in Cellular Transcription 
Brd4 associated with chromatin is a key factor for transcription of a number of 
cellular genes (38, 222, 225).  Probably the most important and well-studied function of 
Brd4 during transcription is recruitment of positive transcription elongation factor B (P-
TEFb) to the transcription initiation complex (86, 223).  P-TEFb is composed of the 
kinase Cdk9 and Cyclin T1 subunits and functions to activate transcription elongation by 
phosphorylating RNA polymerase II (RNAP II) and the transcription inhibitory factors, 
NELF and DSIF (161).  The Brd4 C-terminal domain mediates the interaction with the 
Cdk9 subunit of P-TEFb (19).  When P-TEFb is not associated with Brd4, it is bound in 
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an inhibitory complex with 7SK snRNP and hexamethylene bis-acetamide inducible 1 
(HEXIM1).  Brd4 binding releases P-TEFb from the inhibitory complex and activates 
Cdk9 kinase activity (13, 84). 
Brd4 was recently identified as an atypical kinase that, like P-TEFb, can 
phosphorylate the RNAP II CTD tail at serine 2 (35).  This particular phosphorylation 
activates transcription elongation (14).  It was suggested that Brd4 is the major kinase 
that phosphorylates RNAP II CTD serine 2 during transcription initiation and elongation 
while P-TEFb is mostly important during transcription elongation (35).  It will be 
interesting to discover whether other cellular proteins are phosphorylated by Brd4. 
Brd4 also functions as a protein scaffold, interacting with a number of 
transcription factors and chromatin modifiers (32, 46, 86, 163).  Rahman et al. 
demonstrated that several proteins bind the Brd4 ET domain including GLTSCR1, 
NSD3, and JMJD6 and contribute to Brd4’s transcription activation function 
independently of P-TEFb (163).  Brd4 also interacts with the transcription coactivator, 
Mediator, which is a protein complex that interacts with several general transcription 
factors and serves as a bridge between transcription factors and RNAP II (217).   
1.3.3:  Brd4 as a Mitotic Bookmark 
 The BET proteins are unique in that they remain associated with chromatin during 
mitosis unlike other bromodomain-containing proteins, which are usually displaced from 
mitotic chromosomes (36, 37, 94, 120, 160).  Brd4 functions as a mitotic bookmark, 
binding chromatin near particular set of genes to preserve epigenetic memory between 
cell divisions (38, 229).  Genes important for embryonic development are often 
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bookmarked during mitosis (93).  Therefore, it is not entirely surprising that Brd4 is 
essential for proper embryonic development (78).  Indeed, mice heterozygous for the 
Brd4 gene have several developmental abnormalities and Brd4-null mouse embryos die 
early in development (78).   
A number of the genes bookmarked by Brd4 are important for cell cycle 
progression and Brd4 binding ensures that they are transcribed soon after mitosis (38).  
As a result, altering the level of Brd4 in cells either by siRNA knockdown or ectopic 
expression affects Brd4’s function as a mitotic bookmark and influences cell cycle 
progression (37, 121, 132).  For example, Brd4 siRNA knockdown or depletion with 
antibodies causes a reduction in expression of G1 genes, cell cycle arrest at G2/M, and 
reduced cellular proliferation (37, 132).  In addition, ectopic over-expression of Brd4 
induces G1/S arrest, which is thought to be related to Brd4’s interaction with replication 
factor C1 (RFC1) (121).  Furthermore it was found that either Brd4 knock-down or over-
expression causes aberrant chromosome segregation and failures in cytokinesis, which is 
partially due to Brd4’s regulation of Aurora B kinase expression (225).  Interestingly, 
during mitotic stress induced by nocodozole treatment, JNK activation triggers Brd4 
release from chromatin to prevent genomic instability and allow complete progression 
through mitosis (145).   
1.3.4:  Brd4 Regulates Chromatin Structure 
Post-translational modifications of histone tails are important for regulating 
higher-order chromatin structure and the epigenetic reader proteins that recognize these 
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modifications often mediate the chromatin structure organization (64).  Not surprisingly, 
Brd4 has been shown to regulate cellular chromatin compaction (229).  One study that 
linked Brd4 to chromatin reorganization focused on post-mitotic transcription re-
activation and demonstrated that Brd4 facilitates transcription re-activation after mitosis 
by decompacting chromatin around specific promoters to promote rapid transcription 
activation (229).  Another study from our lab showed that Brd4 is important for 
maintenance of the global chromatin architecture.  In this work, we demonstrated that 
Brd4 knockdown induces global chromatin decondensation while inhibition of Brd4 
binding to chromatin via ectopic expression of the Brd4 bromodomains triggers a 
severely fragmented chromatin morphology (206).  Furthermore, this study demonstrated 
that Brd4 proteins interact intermolecularly on chromatin, suggesting that Brd4 forms a 
molecular scaffold to maintain proper chromatin structure (206).  Most recently it was 
demonstrated that a newly identified Brd4 isoform B interacts with and recruits members 
of the condensin II chromatin remodeling complex to insulate chromatin from DNA 
damage signaling (54).  It will be interesting to determine how Brd4 regulates global 
chromatin structure and whether Brd4 interacts with other chromatin remodeling factors. 
1.3.5:  Brd4 in Human Cancers 
Brd4 is a ubiquitously expressed protein associated with diverse cellular processes 
through its transcriptional regulation of a multitude of cellular genes.  Incidentally, some 
Brd4-associated cellular processes link Brd4 to human cancers.  One of the first studies to 
implicate Brd4 in cancer observed that ectopic expression of Brd4 reduced cell mobility 
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and invasiveness in a breast cancer model and demonstrated that Brd4 controls the 
expression of extra-cellular matrix factors that are linked to cancer cell metastasis (30). 
Brd4 was also identified as a target of a chromosome translocation that results in 
the rare but highly lethal squamous cell cancer, NUT midline carcinoma (NMC) (58).  
This cancer arises from the t(15;19) translocation that fuses the testes-specific gene, 
NUT, to the N-terminal half of Brd4, which includes the bromodomains.  Interestingly, 
some NMC cases were found with fusions of NUT to the Brd3 bromodomains (59).  
NUT fusion to the double bromodomains allows NUT to sequester histone acetyl-
transferases to distinct chromatin foci in order to block global transcription and inhibit 
cellular differentiation (165, 219).  The Brd4-NUT protein also functions to drive c-MYC 
expression to block cellular differentiation (69).  Furthermore, Brd4-NUT increases 
SOX2 protein levels to drive cellular transformation (207). 
NMC tumors are resistant to conventional chemotherapy and there is currently no 
effective cure for this fatal disease (16, 57).  Importantly, the recently developed BET 
bromodomain inhibitor, JQ1, shows great promise as a potential treatment for NMC (51).  
JQ1 and the structurally similar I-BET are cell-permeable small molecules that bind 
within the acetyl-lysine binding pocket of BET protein bromodomains to inhibit the BET 
protein association with acetylated histones (51, 144).  These molecules are highly 
selective for BET family bromodomains with very minimal binding to other 
bromodomain-containing proteins.  Notably, JQ1 induces cellular differentiation and 
growth arrest in NMC cell lines and in a mouse xenograph model of NMC.  In addition, 
JQ1 treatment also causes marked tumor regression and prolonged animal survival (51).   
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Brd4 has been identified as a therapeutic target in several different human cancers 
including acute myeloid leukemia, multiple myeloma, Burkitt’s lymphoma, 
neuroblastoma, and prostate cancer (34, 130, 162, 218, 234).  In cell culture studies of 
these diseases, JQ1 treatment induced potent growth arrest (34, 130, 162, 218, 234).  
Furthermore, JQ1 treatment in an animal model of prostate cancer resulted in greatly 
reduced tumor burden (218).  This anti-tumor effect of Brd4 inhibition was initially 
attributed to Brd4’s important role in regulating MYC, a transcription factor that is often 
mutated or upregulated in a variety of cancers (34, 130).  Indeed, the cancers most greatly 
affected by Brd4 dysregulation tend to be driven by elevated MYC expression (12).   In 
addition, Brd4 knock-down or bromodomain inhibition causes MYC suppression and 
down-regulation of its target genes (34, 130).  More recently, Brd4 was found to also 
control expression of other cancer-related genes including the anti-apoptotic oncoprotein, 
Bcl2, and cell cycle driver, Cdk6, suggesting that cancers controlled by abnormal 
expression of these genes might also be susceptible to Brd4 inhibition (32). 
1.4:  Brd4 Functions in the HPV Life Cycle 
1.4.1:  The E2-Brd4 Interaction 
Brd4 was first identified as an E2-associated factor in a proteomic screen of 
proteins that bind bovine papillomavirus 1 (BPV1) E2TA and this was later confirmed by 
yeast two-hybrid screening (146, 224).  E2 interacts through its transactivation domain 
with the extreme C-terminus of Brd4 (Fig. 1.4, (2)).  The other members of the BET 
family proteins lack this C-terminal region found in Brd4 and they therefore do not 
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interact with E2.   However, it was found that the E2 proteins from all types of 
papillomaviruses interact with Brd4 although with a wide range of binding affinities 
(128).   
After the discovery of E2’s association with Brd4, mutagenesis studies were used 
to identify the E2 regions crucial for Brd4 interaction.  Two conserved amino acids in the 
E2 transactivation domain, arginine 37 and isoleucine 73, were found to mediate E2 
binding to Brd4.  When these sites are mutated to alanines, E2 interaction with Brd4 is 
almost completely abolished (174).  It was also found that while the C-terminal DNA 
binding domain of E2 is not necessary for Brd4 binding, the dimerization function of this 
domain greatly increases E2-Brd4 binding (26).   
Brd4 normally associates with chromatin with a rapid on-off dynamic but when 
bound to E2, Brd4’s association with chromatin is greatly stabilized (36, 129).  
Dimerized E2 further increases Brd4’s affinity for chromatin likely by promoting 
assembly of E2-Brd4 complexes on the chromatin (26).  Similarly, binding of Brd4 to E2 
or ectopically expressed Brd4 CTD stabilizes E2’s association with the E2 binding sites 
in the viral genome (108).  Several studies also demonstrated that Brd4 binding stabilizes 
E2 at the protein level (61, 108).  E2 proteins are relatively short-lived and their levels are 
controlled by ubiquitination and proteosomal degradation (18, 157, 158).  Binding to the 
Brd4 CTD blocks the interaction between E2 and the Cullin-3 ubiquitin ligase, 
contributing to E2 stabilization (232).  It was also shown that E2 is degraded in the 
cytoplasm but Brd4 binding retains E2 in the nucleus and inhibits E2 nuclear export 
(113). 
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Figure 1.4. Model of Brd4 tethering of E2 and the viral episome to cellular chromosomes. 
 
1.4.2:  Brd4’s Function in Papillomavirus Genome Maintenance 
 As described in section 1.2.2, E2 functions to tether viral episomes to host mitotic 
chromosomes to ensure viral genomes are maintained between cell divisions.  For BPV1, 
Brd4 mediates E2 tethering to host mitotic chromosomes (Fig. 1.4, (224)).  Brd4 
normally diffusely coats mitotic chromosomes but in the presence of BPV1 E2, both 
proteins colocalize in a punctate pattern on mitotic chromosomes (129).  When the E2-
Brd4 interaction is abolished by mutating E2 at arginine 37 and/or isoleucine 73, E2 no 
longer associates with mitotic chromosomes (17).  Furthermore, ectopic expression of the 
Brd4 CTD competitively inhibits the E2-Brd4 interaction causing E2’s dissociation from 
mitotic chromosomes (224, 226).   Moreover, expression of the Brd4 CTD causes BPV1 
transformed cells to lose the viral episomes and revert to an untransformed phenotype 
(226). 
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 It was unclear whether Brd4 also functions as the tethering protein during HPV 
infections.  One study examined E2 proteins from several PV types and their association 
pattern with mitotic chromosomes by immunofluorescence (147).  They found that the 
different HPV E2 proteins associate with mitotic chromosomes in distinctive patterns.  
HPV E2’s from the same genera as BPV1 such as HPV1 E2 colocalize with Brd4 in 
punctate dots along the chromosome arms.  However, the E2 from other HPV subtypes 
were found associated with pericentromeric regions of chromosomes and the E2 from 
high-risk HPV types such as HPV16 and 18 could not be detected on mitotic 
chromosomes by immunofluorescence unless the cells were pre-extracted before fixation.  
After this treatment, HPV16 and 18 E2 were found bound to pericentromeric regions of 
host chromosomes but there is still question about whether pre-extraction alters E2 
nuclear localization.   
Another group sought to determine whether inhibiting the Brd4 interaction with 
HR-HPV E2 protein affects viral episome tethering to mitotic chromosomes (2).  They 
used a Brd4 CTD peptide fused to HIV Tat to deliver the peptide into cells that maintain 
either HPV16 or HPV31 genomes to abrogate the E2-Brd4 interaction.  By analyzing 
metaphase spreads, they found that the Brd4 CTD fusion peptide abolished the 
association of HPV16 or 31 episomes with mitotic chromosomes, while a Brd4 CTD 
mutant peptide that does not bind E2 did not affect episome tethering to chromosomes. 
These results suggest that the Brd4 interaction with HR-HPV E2 proteins is necessary for 
viral genome tethering to mitotic chromosomes.   
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1.4.3:  Brd4’s Functions in Papillomavirus Transcription and Replication 
 E2 is the major transcription regulatory factor that functions to either activate or 
repress viral gene expression (see section 1.2.4).  Mutational analyses identified amino 
acids in the E2 transactivation domain important for E2-mediated transcription activation.  
Two highly conserved residues, arginine 37 and isoleucine 73, were found to be crucial 
for E2 transactivation function since alanine substitutions at these sites rendered the E2 
protein transcriptionally inactive (168, 213).  Interestingly, it was later found that these 
two residues are also necessary for binding to Brd4.  Subsequent studies discovered that 
Brd4 is essential for E2 transcription activation function (17, 128, 174).  Indeed, both 
Brd4 knock-down or abrogation of the E2-Brd4 interaction by ectopic expression of Brd4 
CTD inhibited transcription activation by E2 from several PV subtypes (128, 174, 179).   
 The R37A and I73A E2 point mutants were also found to abolish E2-dependent 
transcription repression, indicating a role for Brd4 in E2 transcriptional repression (216).  
Subsequent studies found that siRNA knock-down of Brd4 or disruption of the E2-Brd4 
interaction using Brd4 CTD both inhibited E2’s transcription repression function, 
confirming Brd4 as an important player in repression of PV gene expression (173, 184, 
216). 
  In cervical cancer cells where the HPV genome is integrated into the host DNA, 
the E2 gene is invariably missing or disrupted so that E2 is no longer expressed.  This is 
thought to be crucial for cervical cancer development since loss of E2 triggers 
derepression of the viral oncogenes (see section 1.1.2).  This dysregulated expression of 
E6 and E7 was found to require Brd4 recruitment of P-TEFb to the viral oncogene 
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promoter integrated in the host genome (220).  Importantly, this study discovered that E2 
inhibits Brd4’s interaction with P-TEFb and ectopic expression of E2 in HeLa cells 
prevents Brd4 recruitment of P-TEFb to the integrated viral promoter, providing a 
mechanism for E2-mediated repression in cervical cancer cells.   
 Although, Brd4 functions to recruit P-TEFb to activate the integrated viral early 
promoter in cervical cancer cells, it is still not known how Brd4 functions in transcription 
activation of episomal genomes during natural HPV infection.  The papillomavirus 
episomes associate with cellular histones to form nucleosomes so it is possible that Brd4 
interacts with these nucleosomes on the viral genomes to recruit transcription factors or 
chromatin modulator proteins (49, 167).  Additionally, two studies demonstrated that E2 
associates with transcriptionally active cellular chromatin through its interaction with 
Brd4, suggesting that E2 may bind to Brd4 to ensure that the viral episomes are retained 
in transcriptionally active regions of the nucleus to avoid transcriptional silencing (85, 
87).  Interestingly, these studies also showed that Brd4 associates with cellular chromatin 
near common fragile sites, which are prone to DNA damage, providing evidence that 
Brd4 recruits papillomavirus genomes to these sites to facilitate viral genome replication 
(87). 
1.4.4:  Brd4’s Association with Other Viruses 
 Brd4 and some of the other BET proteins are targeted by other viruses besides the 
papillomaviruses.  The herpesviruses, Kaposi’s sarcoma-associated herpes virus (KSHV), 
and Epstein-Barr virus (EBV), encode viral proteins that not only have similar functions 
to the papillomavirus E2 protein but also interact with Brd4 (115, 149, 202, 227).  The 
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KSHV latency-associated nuclear antigen (LANA1) protein regulates KSHV 
transcription and also tethers the viral genome to host mitotic chromosomes.  Brd4 was 
found to interact with LANA1 on mitotic chromosomes, suggesting that it might be 
important for KSHV viral genome tethering to cellular chromosomes (227).  Similarly, 
EBV encodes the Epstein-Barr nuclear antigen 1 protein (EBNA1), which functions in 
viral replication, viral genome tethering to cellular mitotic chromosomes, and viral 
transcription regulation (115).  Brd4 binding to EBNA1 was shown to be important for 
EBNA1’s transactivation function (115).  Brd4 also binds the family of repeats (FR) 
enhancer regions within the EBV genome to possibly regulate viral transcription (115). 
 During human immunodeficiency virus (HIV) infection, the viral TAT protein 
activates expression of the viral genes by recruiting P-TEFb to the integrated HIV 
genome.  Brd4 was shown to compete with TAT for P-TEFb binding and effectively 
inhibit transcription of HIV genes (19).  More recently, there is evidence that blocking 
Brd4 function with the BET inhibitors such as JQ1 could be a useful tool to reactivate 
latent HIV (11, 22).  Brd2 was also identified as an important suppressor of HIV 
transcription in latently infected cells and knock-down of Brd2 or treatment with the BET 
inhibitors also contributed to HIV latency reactivation (22). 
 Merkel cell polyomavirus (MCV) is a relatively newly discovered virus that is 
associated with about 80% of Merkel cell carcinoma cases (MCC) (77).  Like other 
polyomaviruses, MCV encodes a large tumor (LT) antigen as well as a few alternatively 
spliced truncations of LT (105).  The LT protein is important for regulating viral genome 
replication and viral transcription (105).  Our group discovered that the MCV LT protein 
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binds Brd4, which recruits RFC1 protein to the viral replication complex to support MCV 
genome replication (209).   
Most recently, Brd4 was identified as an important interaction partner for the 
murine leukemia virus (MLV) integrase protein (33, 181).  As described in previous 
sections, Brd4 binds acetylated histones and is mostly associated with transcriptionally 
active regions of cellular chromatin (36, 204).  In the above studies, Brd4 was shown to 
bind the MLV integrase protein to direct viral integration near cellular transcriptional 
start sites, which ensures the viral genes are expressed and not silenced (33, 181). 
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CHAPTER 2:  Analysis of the HPV16 E2 and 
Brd4 Interaction Using BiFC 
	  
	  
 Research presented in this chapter was accomplished in collaboration with a 
postdoctoral fellow in our laboratory, Ranran Wang, with equal contribution.  I have 
contributed to the experimental design and execution, and manuscript writing for this 
publication.  Together with Ranran, I have ensured that the BiFC signal was specific for 
the E2-Brd4 complex (Figure 2.1, 2.2), examined the E2-Brd4 BiFC in interphase and 
mitotic cells (Figure 2.3), and analyzed the E2-Brd4 BiFC signal in the presence of the 
Brd4 C-terminal domain (Figure. 2.4).  I conducted the experiments testing the effect of 
both the HPV genome and JQ1(+) on E2-Brd4 BiFC signal intensity and chromatin 
association (Figure 2.5, 2.6). 
	  
	  
	  
	  
This research was originally published in PLoS ONE.  Christine M. Helfer*, 
Ranran Wang*, and Jianxin You.  Analysis of the Papillomavirus E2 and Bromodomain 
Protein Brd4 Interaction Using Bimolecular Fluorescence Complementation.  PLoS ONE 
2013. 8(10): e77994.  *equal contribution 
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2.1:  Chapter Summary 
	  
The human papillomavirus (HPV) vaccines effectively protect against new 
infections of up to four HPV subtypes.  However, these vaccines are not protective 
against many other clinically relevant HPV subtypes and are ineffective at treating 
established HPV infections.  There is therefore a significant need for antiviral treatments 
for persistent HPV infections.  We hypothesize that the complex between the HPV E2 
protein and Brd4 would be an effective anti-HPV drug target since this pair mediates 
several viral processes including genome maintenance, replication, and transcription of 
HPV proteins.  Using bimolecular fluorescence complementation (BiFC) technology, we 
observe the HPV16 E2 and Brd4 interaction on cellular chromatin in interphase and 
mitotic cells. The E2-Brd4 BiFC is significantly diminished by mutating the Brd4 
binding sites in E2 or by a dominant negative inhibitor of the E2-Brd4 interaction, 
demonstrating that BiFC may be useful for identifying inhibitors of protein-protein 
interactions.  Importantly, when Brd4 is released from chromatin using the bromodomain 
inhibitor JQ1(+), the E2-Brd4 complex relocates into foci that no longer associate with 
mitotic chromosomes, pointing to JQ1(+) as a promising antiviral inhibitor of HPV 
genome maintenance during HPV persistent infection. 
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2.2:  Introduction 
	  
Infection by the high-risk human papillomavirus subtypes is associated with 
several types of cancer including various anogenital cancers as well as head and neck 
cancers (236).  Papillomaviruses infect undifferentiated basal epithelial cells where the 
virus establishes a persistent infection.  In the majority of cases, infection is eventually 
cleared by the host immune system but in the rare cases when the infection is allowed to 
persist for several years, mutations can arise that develop into cancer (41).     
There are now two commercially available prophylactic HPV virus-like particle 
vaccines that protect against HPV types 16 and 18 (Cervarix) and HPV types 6, 11, 16, 
and 18 (Gardasil).  Although the vaccines effectively prevent initial infections, they are 
ineffective at curing persistent infections (10, 198).  Alternative approaches are therefore 
needed for treating ongoing infections.   
Currently, there are no virus-specific antiviral therapies to cure HPV infection.  
The E1 helicase protein is the only enzyme encoded by papillomaviruses making it a 
promising target for drug design.   However, small molecule inhibitors against E1 
ATPase activity were unfortunately found to be inactive in cellular assays (190, 212).  
The highly conserved papillomavirus E2 protein interacts with E1 and is required for 
several viral functions making this protein another promising candidate for drug 
targeting.  Indeed, White et al. identified small molecule inhibitors of the E2-E1 
interaction for HPV 6 and 11, demonstrating the feasibility of small molecule inhibitors 
of virus-mediated protein-protein interactions (211).   
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The papillomavirus E2 protein is an attractive target for drug design because it 
mediates several viral processes during PV infection.  E2 is crucial for viral genome 
replication since it recruits the E1 helicase protein to the viral origin (171).  Additionally 
E2 both positively and negatively regulates transcription from the viral promoter (60, 
192, 194).  E2 also functions in viral genome maintenance during persistent infection by 
tethering PV genomes to mitotic chromosomes to ensure their faithful partitioning into 
daughter cells during cell divisions (15, 82, 112, 159, 183). 
An important E2 interacting partner is Brd4 (224).  The Brd4 C-terminal domain 
binds to the E2 transactivation domain and helps E2 perform many of its viral functions 
(2, 128).  Our laboratory has shown that Brd4 is an essential E2 cofactor during HPV 
genome replication (208) (see Chapter 3).  Brd4 is also recruited by E2 to help regulate 
viral transcription (128, 174, 184, 216).  In addition, Brd4 and BPV1 E2 interact on 
mitotic chromosomes to mediate viral genome maintenance (Fig. 1.4, (17, 24, 129, 224)).   
Since E2 in complex with Brd4 controls multiple important HPV functions, it has 
been proposed that antiviral inhibitors targeting this interaction would likely abrogate the 
HPV life cycle and clear the infection (190).  In support of this hypothesis, past studies 
have demonstrated that blocking E2-Brd4 with either Brd4 binding-deficient E2 mutants 
or expression of Brd4 CTD impairs viral transcription activation and HPV genome 
replication (128, 174, 208).  Furthermore, abrogation of the E2-Brd4 interaction abolishes 
tethering of both HPV16 and HPV31 viral episomes to mitotic chromosomes, which 
could eventually result in cell clearance of the virus genomes as cells divide (2).   
30 
	  
In this work, we utilized bimolecular fluorescence complementation (BiFC) 
technology to study the Brd4 interaction with HPV16 E2 in live and fixed cells.  This 
technique allowed us to visualize physiological levels of E2 and Brd4 interacting in live 
cells at all cell cycle stages and demonstrated Brd4’s involvement in E2 tethering to 
mitotic chromosomes. Furthermore, the utility of BiFC for drug screening was 
demonstrated using Brd4 CTD as an E2-Brd4 inhibitor that effectively abolishes E2-Brd4 
BiFC. Finally, we show that the bromodomain inhibitor, JQ1(+), releases E2-Brd4 BiFC 
from mitotic chromosomes, indicating this drug as a potential agent to interrupt and clear 
HPV persistent infection. 
 
2.3:  Results 
	  
2.3.1:  BiFC signal is specific for the Brd4-E2 interaction  
 
 Brd4 is the molecular tether for BPV1, linking E2 and the viral genome to host 
mitotic chromosomes to ensure stable maintenance of the viral genomes between cell 
divisions (17, 24, 129, 224).  However, despite the fact that Brd4 interacts with the E2 
proteins of the human papillomaviruses, it is still unclear whether Brd4 also plays a role 
in episome tethering for the HPV subtypes (2, 129, 224).  We employed bimolecular 
fluorescence complementation (BiFC) technology to study the interaction between HPV 
type 16 E2 and Brd4 and determine the importance of Brd4 for tethering HPV16 E2 to 
mitotic chromosomes.  BiFC is a useful method to examine protein-protein interactions in 
live and fixed cells.  The technique involves fusing the proteins of interest individually to 
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complementary fragments of a fluorescent protein and expressing them together in cells.  
Interaction between the two fusion proteins brings the fluorescent protein fragments 
within close proximity, allowing the fluorescent protein to reform and emit fluorescent 
signal (95).  With this method, specific protein interactions can be identified and located 
within live or fixed cells through visualization of fluorescent signal. 
 For these studies, Brd4 was fused to the N-terminal portion (VN) of the yellow 
fluorescent protein, Venus, while either HPV16 E2 or BPV1 E2TA was fused to the C-
terminal portion of Venus (VC).  The resulting constructs both contain Flag and 
hemagglutinin (HA) epitope tags to monitor the proteins in cells.  We first confirmed that 
the BiFC signal in our experiments was specific for the E2-Brd4 interaction.  The HPV-
negative cervical cancer cell line, C33A, was used in these studies since it provides a 
similar cellular environment that human papillomaviruses encounter during natural 
infection.  We and other investigators have previously observed by immuofluorescence 
staining of C33A cells that Brd4 localizes in punctate speckles throughout the nucleus 
and when E2 is present, it colocalizes with Brd4 in these nuclear speckles (129, 224).   
Interestingly, in live C33A cells cotransfected with VN-Brd4 and either VC-E2TA or 
VC-16E2, we could detect the E2-Brd4 BiFC signal in nuclear speckles, demonstrating a 
real-time interaction of BPV1 E2TA and HPV16 E2 with Brd4.  Similar results were seen 
in fixed cells, which allowed us to examine the cells under high magnification (Fig. 2.1 
A).  In contrast to the above results, cells cotransfected with the empty VN construct and 
either VC-E2TA or VC-16E2 did not produce any BiFC signal despite the high 
expression of these constructs measured by anti-Flag immunostaining and 
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immunoblotting (Fig. 2.1 A, B).  In addition, co-expressing VN-Brd4 and the empty VC 
construct also did not generate BiFC signal (data not shown).  These observations 
confirmed that the BiFC signal was generated through specific interaction between Brd4 
and E2. 
 To further test the specificity of E2-Brd4 BiFC, we examined E2 mutants 
defective in Brd4 binding.  E2TR is a truncated protein expressed from the BPV1 E2 
ORF, which lacks the transactivation domain and functions as a repressor of E2TA 
activity during the viral life cycle (114, 135).  This protein also lacks the Brd4 binding 
domain and, therefore, does not interact with Brd4 (224).  For HPV16 E2, the 
R37A/I73A double point mutant has been shown to bind Brd4 with much lower 
efficiency than wild type E2 (128).  These E2 proteins were compared with E2TA and 
wild type 16E2 for interaction with Brd4 using BiFC.  C33A cells were cotransfected 
with VN-Brd4 and one of the VC-E2 proteins (E2TA, E2TR, 16E2, or 16E2 
R37A/I73A).  Western blot analysis showed that expression levels were comparable 
between the E2 proteins except E2TR, which consistently had lower expression than the 
other E2 proteins (Fig. 2.2 C).  Importantly, the VN-Brd4 fusion protein expressed at a 
much lower level than endogenous Brd4, suggesting that it is not likely to induce an over-
expression artifact (Fig. 2.2 D).  Co-expression of Brd4 with the wild type E2 proteins 
generated a strong BiFC signal in nuclear speckles (Fig. 2.2 A).  In contrast, co-
expression of Brd4 with the E2 mutants only showed dim BiFC nuclear foci (Fig. 2.2 A). 
The cells were also immunostained with anti-Flag antibody to visualize expression of the 
Flag-tagged Venus fusion proteins and the percentage of Flag-positive cells with BiFC 
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signal was quantified. While virtually all E2TA- or 16E2 WT-transfected cells had robust 
BiFC signal, the majority of cells transfected with E2TR or 16E2 R37A/I73A were either 
negative for BiFC signal or had very dim BiFC nuclear speckles, which were counted as 
positive BiFC in the quantification (Fig. 2.2 B). Notably, the dim BiFC signal of 16E2 
R37A/I73A-Brd4 or E2TR-Brd4 could only be detected in cells with very high 
expression of Venus fusion proteins (as indicated by the strong Flag signal). The high 
quantities of Brd4 and E2 mutant Venus fusion proteins present together in cells could 
contribute to the high BiFC background, which was also observed in previously 
published studies (98, 143). The Brd4 and 16E2 R37A/I73A BiFC also suggests that, 
while the affinity of this E2 mutant for Brd4 is greatly reduced, it still retains some ability 
to bind Brd4. This is supported by co-immunoprecipitation showing that the HPV16 E2 
R37A/I73A mutant could pull-down a detectible amount of Brd4 protein (Fig. 2.2 E). 
These data demonstrate that breaking the E2-Brd4 interaction by mutagenesis could 
greatly reduce the E2-Brd4 BiFC signal, confirming that the BiFC signal was specifically 
generated through the E2-Brd4 interaction. 	     
2.3.2:  E2 and Brd4 interact during interphase and mitosis 
 Previous immunofluorescence analyses have shown that Brd4 interacts with E2 
from various papillomavirus types during interphase and mitosis (128).  However, the 
cell cycle phases at which HPV16 E2 and Brd4 interact are less clear.  By 
immunofluorescence, we detected 16E2 colocalized in small speckles on chromatin with 
endogenous Brd4 in C33A interphase cells (Fig. 2.3 A).  Similarly, in C33A cells 
cotransfected with VN-Brd4 and VC-16E2 WT plasmids, E2-Brd4 BiFC fluorescence 
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was detected in small speckles on interphase chromatin (Fig. 2.3 B).  The 
immunofluorescence technique was not sensitive enough to detect HPV16 colocalized in 
speckles with endogenous Brd4 on mitotic chromosomes (data not shown).  However, 
using BiFC technology, we observed HPV16 E2-Brd4 BiFC fluorescence in small dots 
on mitotic chromosomes from all phases of mitosis (Fig. 2.3 B).  This result was also 
observed with VN-Brd4 and VC-E2TA (data not shown).  In cells transfected with VC-
16E2 and VN empty vector, neither BiFC signal nor Flag-16E2 immunofluorescence was 
detected on mitotic chromosomes (Fig. 2.3 C).  This experiment demonstrates that BiFC 
is a useful tool to study the E2-Brd4 interaction in live cells throughout the cell cycle.  In 
addition, this study shows that HPV16 E2 and Brd4 interact on chromosomes during 
mitosis and suggests a role for Brd4 in HPV16 E2-mediated episome tethering and 
maintenance in host cells. 
2.3.3:  Brd4 CTD disrupts E2-Brd4 BiFC 
	   Papillomavirus E2 proteins interact with the Brd4 CTD and previous studies 
demonstrated that the Brd4 CTD could competitively inhibit the E2 interaction with full-
length Brd4 and disrupt multiple viral processes (2, 174, 216, 224).  We sought to test 
whether the CTD could abrogate E2-Brd4 BiFC signal with the thought that this 
technique could be used to screen small molecule inhibitors of this important interaction.  
C33A cells were cotransfected with the VN-Brd4 plasmid, one of the VC-E2 plasmids, 
and a construct that expressed either Xpress-tagged Brd4 CTD or LacI, which served as a 
negative control.  Both the Brd4 CTD and LacI proteins contained nuclear localization 
sequences to focus the proteins in the nucleus.  In live cells, there was an obvious 
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reduction in the number of BiFC positive cells in the CTD transfections compared to cells 
transfected with LacI (data not shown).  We further examined the BiFC signal in fixed 
cells co-stained with HA to detect the E2 and Brd4 fusion proteins and Xpress to detect 
CTD or LacI (Fig. 2.4 A and B).  As seen in live cells, expression of LacI did not affect 
E2-Brd4 BiFC signal.  However, despite the lower expression of CTD measured by 
immunoblotting (Fig. 2.4 D), there was a marked decrease in cells with BiFC 
fluorescence in CTD-positive cells (Fig. 2.4 A and B).  The percentage of HA- and 
Xpress-positive cells with BiFC signal was quantified, revealing a significant reduction in 
BiFC-positive cells when CTD was expressed as compared to LacI (Fig. 2.4 C).  This 
study shows that a dominant negative inhibitor of the E2-Brd4 interaction could disrupt 
E2-Brd4 BiFC, further confirming that the BiFC signal is specifically generated through 
the E2-Brd4 interaction.  Additionally, this experiment demonstrates the potential for 
BiFC as a technique to identify inhibitors of this important interaction.  
2.3.4:  The HPV genome enhances E2-Brd4 BiFC 
During natural papillomavirus infection, E2 forms a homodimer and binds E2 
binding sites in the long control region of the viral genome (44).  We were curious 
whether the presence of the HPV genome would affect E2-Brd4 BiFC since it was 
previously shown that Brd4 interacts more efficiently with dimerized E2 proteins (26).  In 
this experiment, we cotransfected C33A cells with VC-16E2, VN-Brd4, and either empty 
vector or the HPV16 genome at a 1:2 ratio (BiFC constructs:HPV16 genome/vector) to 
increase the probability that cells with BiFC signal also contain HPV16 genome or empty 
vector.  Intriguingly, cells transfected with the HPV16 genome had a more than two-fold 
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increase in E2-Brd4 BiFC signal intensity compared to cells transfected with empty 
vector.  (Fig. 2.5 A, B) From this result, we suspect that the HPV genome promotes E2 
dimerization, which enhances E2-Brd4 interaction.  However, it is also possible that other 
viral mRNA or proteins expressed from the HPV genome might somehow promote the 
E2-Brd4 interaction.  Further experiments are needed to better understand this result. 
2.3.5:  JQ1(+) treatment releases E2-Brd4 BiFC proteins from mitotic chromosomes 
 Brd4 associates with acetylated histones through its double bromodomains and 
the chemical compound JQ1(+) effectively inhibits this association, releasing Brd4 from 
chromatin (51).  Since Brd4 is thought to tether E2 to mitotic chromosomes for viral 
genome maintenance, we hypothesized that releasing Brd4 from chromosomes by JQ1(+) 
would disrupt the association of the E2-Brd4 complex with mitotic chromosomes.  To 
test this, we used the BiFC system to monitor the effect of JQ1(+) treatment on the E2-
Brd4 interaction with mitotic chromosomes and interphase chromatin.  C33A cells were 
cotransfected with the VN-Brd4 and VC-16E2 plasmids and 24 hours later treated with 
500nM JQ1(+) or the inactive stereoisomer JQ1(-) for various lengths of time.  
Interestingly, within 30 minutes of JQ1(+) treatment, the E2-Brd4 BiFC signal was no 
longer in the chromatin-associated speckles but instead formed punctate foci that grew 
larger with increased incubation in JQ1(+) (Fig. 2.6 A).    In contrast, E2-Brd4 BiFC 
signal remained in the chromatin-associated speckles in cells treated with JQ1(-) (Fig. 2.6 
A).   
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 It was important to rule out the possibility that these punctate foci were non-
specific aggregates of the BiFC proteins.  We therefore repeated the above experiment 
but transfected cells with the VN-Brd4 plasmid and VC control construct followed by 
JQ1(+) treatment starting at 24 hours post transfection.  As was seen in Fig 2.1, no BiFC 
fluorescence was formed with these two proteins (data not shown).  Furthermore, the 
Flag immunofluorescence staining of the BiFC constructs was diffuse in the nucleus in 
contrast to the enrichment of Flag proteins in large foci seen for the VN-Brd4/VC-16E2 
transfected cells treated with JQ1(+) (Fig. 2.6 A).  This result suggests that these punctate 
foci are not likely to be non-specific protein aggregates but specifically form between E2 
and Brd4 upon JQ1(+) treatment. 
 As another way to confirm the specificity of these foci, we determined whether 
the E2-Brd4 BiFC proteins in the large foci would return to chromatin-associated 
speckles when JQ1(+) was washed away from the cells.  Cells transfected with the E2 
and Brd4 BiFC plasmids were incubated with JQ1(+) for 24 hours and then thoroughly 
washed and cultured in media lacking JQ1(+) for up to three hours.  Surprisingly, the E2-
Brd4 BiFC began returning to the small speckles on chromatin within five minutes of 
removing JQ1(+) and, in most cells, was completely restored to its usual speckled pattern 
after one hour (Fig. 2.6 A).  From this result we concluded that these large foci are not 
likely to be non-specific protein aggregates but rather large, reversible E2-Brd4 
complexes formed specifically when Brd4 is released from chromatin. 
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 We next examined the effect of JQ1(+) on the 16E2-Brd4 association with mitotic 
chromosomes.  C33A cells were transfected with the 16E2 and Brd4 BiFC constructs 
and, 48 hours later, treated with 500 nM JQ1(+) or JQ1(-) for only 1 hour to minimize the 
drugs’ effect on cell cycle and BiFC protein levels.  Similar to mitotic cells without drug 
treatment in Fig. 2.3, mitotic cells treated with JQ1(-) had 16E2-Brd4 BiFC in small dots 
associated with the chromosomes in 36 out of 51 (70.6%) of transfected mitotic cells 
(Fig. 2.6 B).  Conversely, the 16E2-Brd4 BiFC in mitotic cells treated with JQ1(+) was in 
large foci clearly dissociated from the chromosomes and only 6 out of 50 (16.0%) 
transfected mitotic cells had E2-Brd4 BiFC colocalized with chromosomes (Fig. 2.6 B).  
These foci were likely dissociated from the chromosomes but their signals superimposed 
on the chromosomes under the microscope. Since it was not possible to determine for 
sure that these foci were dissociated from chromosomes, we counted these cells as having 
E2-Brd4 BiFC still associated with chromatin making the above quantification a 
conservative estimate.  Interestingly, we observed much fewer E2-Brd4 BiFC foci in the 
JQ1(+) treated cells compared to the JQ1(-) treated cells, suggesting that when 
dissociated from chromosomes during mitosis, the E2-Brd4 interaction might become 
less stable.  It is also important to note that the Flag staining was completely excluded 
from the mitotic chromosomes in JQ1(+) treated cells, suggesting that 16E2 tethering to 
mitotic chromosomes is dependent on Brd4’s associated with chromatin.  We observed 
similar JQ1(+) effects on the E2TA-Brd4 association with mitotic chromosomes (data not 
shown).  These results reveal the potential of JQ1(+) as a possible antiviral for disruption 
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of HPV episome maintenance during persistent infection and suggest an important role of 
Brd4 for tethering HPV16 E2 to mitotic chromosomes. 
 
2.4: Discussion 
 Here, we used BiFC technology to demonstrate that HPV16 E2 and Brd4 interact 
on interphase chromatin and mitotic chromosomes.  This association with mitotic 
chromosomes is abolished when Brd4 tethering to chromatin is inhibited by JQ1(+), 
demonstrating the potential of JQ1(+) as an antiviral agent to treat HPV persistent 
infections by abrogating episome maintenance.  We also confirmed through these 
findings that Brd4 is an important factor for HPV16 E2 tethering to mitotic chromosomes 
and is therefore likely important for HPV16 episome maintenance between cell divisions.  
 Brd4 is known as the molecular tether for BPV1 episome maintenance but it 
appears that the tethering process for the HPV subtypes is more complex and involves 
multiple cellular factors.  Besides Brd4, other proteins such as TopB1 and ChlR1 have 
been implicated in HPV episome maintenance (23, 40, 153).  One question that remains 
is determining the specific function of Brd4 and these other proteins during episome 
tethering.  It will also be important to determine if these proteins have redundant roles in 
episome maintenance or if they are each essential for the tethering process.  From our 
JQ1(+) study, since no E2 immunofluorescent signal was detected on mitotic 
chromosomes in the presence of JQ1(+), we predict that Brd4 plays an essential role in 
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E2 tethering to chromosomes.  Further investigation is required to determine the 
functional importance of the other factors involved in HPV episome maintenance. 
 We and other investigators have observed that HPV16 E2 interacts very weakly 
with Brd4 compared to other papillomavirus E2s such as BPV1 E2 (128).  However, we 
saw a dramatic increase in E2-Brd4 BiFC signal intensity in the presence of the HPV 
genome.  The simplest explanation for this is supported by work from others showing 
that E2 dimerizes when binding the HPV genome and as a dimer, E2 binds Brd4 more 
efficiently (26, 44).  However, it is also worth noting that the HPV genome is known to 
associate with histones and form a structure similar to cellular chromatin that Brd4 likely 
interacts with through its double bromodomains (49, 167).   The functional consequences 
of Brd4 binding HPV chromatin have not been investigated but it is possible that Brd4 
binding viral chromatin could stabilize its interaction with E2.  Additionally, one or more 
of the viral proteins expressed from the viral genome might have an unknown function in 
regulating the E2-Brd4 interaction but further analysis is needed to confirm this 
explanation.  Nevertheless, our finding suggests that during infection when the viral 
episomes are present, the HPV16 E2 interaction with Brd4 is likely a much stronger 
interaction than was previously appreciated. 
 In C33A cells, Brd4 bound to cellular chromatin appears as nuclear speckles by 
immunofluorescence and E2 colocalizes with Brd4 in these speckles.  Remarkably, upon 
treatment with JQ1(+), the E2 and Brd4 BiFC partners relocate into large, punctate 
spheres that are reversible when JQ1(+) is removed.  Interestingly, VN-Brd4 and VC-
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Brd4 BiFC partners also form nuclear spheres after treatment with JQ1(+) (data not 
shown) and, furthermore, we have observed that these punctate spheres formed by the 
Brd4-Brd4 and E2-Brd4 BiFC partners also contain PML protein (data not shown).  This 
result suggests that when blocked from binding chromatin, Brd4 and any associated 
proteins localize to PML nuclear bodies where the proteins might be post-translationally 
modified or maybe simply stored in the nuclear bodies.  Additional studies are necessary 
to better understand this result. 
 BET inhibitors like JQ1(+) are currently being tested in clinical trials as a 
potential treatment for various cancers such as AML and NUT midline carcinoma (231).  
In our experiments, we found that E2 was no longer tethered to mitotic chromosomes 
upon treatment with JQ1(+).  This is important because during a persistent HPV 
infection, the virus relies on the tethering of E2 to chromosomes to ensure that its 
genomes are maintained and not lost during the latest stage of mitosis when the nuclear 
envelope reforms.  It is therefore possible that JQ1(+) treatment of cells with persistent 
HPV infection could abolish tethering of E2 and the viral genome to host chromosomes 
resulting in a gradual loss of HPV genomes in each cell and eventual clearance of the 
infection.  However, as will be discussed in later chapters, further studies in naturally 
infected cells are necessary to determine the overall impact of JQ1(+) on the HPV life 
cycle especially since Brd4 is involved in HPV genome replication and viral transcription 
regulation. 
2.5:  Figures 
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Figure 2.1 
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Figure 2.1.  The BiFC signal is specifically generated through the E2-Brd4 
interaction. (A) C33A cells were cotransfected with pairs of Venus N constructs (VN or 
VN-Brd4) and Venus C constructs (VC-E2TA or VC-16E2) as indicated on the right 
panel. Forty-eight hours post transfection, the cells were fixed and stained with anti-Flag 
antibody (red) and DAPI. Bar, 10 μm.  (B) C33A cells were transfected as described in 
(A) and protein lysates were immunoblotted using anti-HA or anti-Actin antibodies. 
Arrows mark the VC-E2s or VN constructs expressed in cells. 
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Figure 2.2 
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Figure 2.2. The E2-Brd4 BiFC signal is inhibited by mutating the Brd4 binding sites 
in E2. (A) C33A cells were cotransfected with VN-Brd4 and Venus C BiFC constructs 
(VC-E2TA, VC-E2TR, VC-16E2, or VC-16E2 R37A/I73A (16E2M)) as indicated on the 
right panel. Forty-eight hours post transfection, the cells were fixed and stained with anti-
Flag antibody (red) and DAPI. Bar,10 μm. (B) For each transfection in (A), the 
percentage of cells showing BiFC signal was quantified from approximately 200 
positively transfected cells. Average and standard deviation were calculated from three 
independent experiments.  (C) C33A cells were either untreated or transfected as 
described in (A) and protein lysates were immunoblotted using anti-HA or anti-Actin 
antibodies. Arrows mark the VC-E2 constructs expressed in cells.  (D) Protein lysates 
from untreated C33A cells or cells transfected with VN-Brd4 and VC-16E2 were 
immunoblotted using anti-Brd4 or anti-Actin antibodies. (E) C33A cells were 
cotransfected with Flag-HA-tagged 16E2 WT, R37A/I73A (16E2M), or empty vector as 
well as Xpress-tagged Brd4.  At 48 hour post transfection, nuclear extracts were collected 
and used in Flag (M2) immunoprecipitations.  The input and IP samples were analyzed 
by Western blotting using anti-HA and anti-Xpress antibodies. 
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Figure 2.3 
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Figure 2.3. HPV16 E2 and Brd4 interact on chromatin in interphase and mitotic 
cells.  (A) C33A cells were transfected with GFP-16E2 and 48 hours post transfection 
were fixed and stained with anti-Brd4C antibody (red) and DAPI. (B) C33A cells were 
cotransfected with VN-Brd4 and VC-16E2 BiFC constructs.  Forty-eight hours post 
transfection, cells were fixed and stained with anti-Flag antibody (red) and DAPI. Merge 
1 is a merge of the BIFC and DAPI panels and Merge 2 is a merge of BIFC, Flag and 
DAPI panels. (C) C33A cells were cotransfected with Venus N and VC-16E2 BiFC 
constructs.  Forty-eight hours post transfection, the cells were stained with anti-Flag 
antibody (red) and DAPI. Bar, 5 μm. 
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Figure 2.4 
 
49 
	  
Figure 2.4.  Brd4 CTD effectively disrupts the E2-Brd4 interaction measured by 
BiFC.  (A, B) C33A cells were cotransfected with VN-Brd4, VC-E2TA or VC-16E2, and 
either Xpress-LacI or Xpress-Brd4 CTD constructs as indicated on the right panel.  Forty-
eight hours post transfection, the cells were fixed and stained with anti-HA antibody (red) 
and anti-Xpress antibody (blue).  (C) For each transfection in (A) and (B), the percentage 
of cells showing BiFC signal was quantified from approximately 100 Xpress- and HA-
positive cells. Average and standard deviation were calculated from three independent 
experiments.  Bar, 5 μm. (D) C33A cells were transfected as described in (A) and (B). 
Protein lysates were immunoblotted using anti-HA, anti-Xpress, or anti-Actin antibodies.  
Arrows mark the VC-E2s, Xpress-LacI, or Xpress-CTD constructs expressed in cells. 
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Figure 2.5 
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Figure 2.5. The E2-Brd4 BiFC signal is enhanced by the presence of HPV16 genome. 
(A) C33A cells were cotransfected with VN-Brd4, VC-16E2, and either pUC19 or 
pEFHPV-16W12E at a 1:2 ratio.  Forty-eight hours post transfection, cells were fixed and 
stained with anti-Flag antibody (red) and DAPI.  Bar, 5 μm. In the vector control, the 
BiFC signal is dimmer than in previous figures because there is much less E2/Brd4 BiFC 
DNA transfected. (B) Scatter plot of the average BiFC signal intensity divided by nucleus 
area in cells transfected as in (A). Data were collected from 50 vector transfected cells 
and 50 HPV16 genome transfected cells using ImageJ. This experiment was repeated 
twice with similar results. Bars indicate the mean of all cells examined.   
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Figure 2.6 
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Figure 2.6.  Releasing Brd4 from chromatin by JQ1(+) abolishes the E2-Brd4 
interaction on mitotic chromosomes.  (A) C33A cells were cotransfected with VN-Brd4 
and VC-16E2 and treated with 500 nM JQ1(-) or JQ1(+) at 24 hours post transfection.  
Forty-eight hours post transfection, cells were either fixed immediately (before wash) or 
washed several times and cultured for the times indicated on the right panel.  All cells 
were fixed and stained with anti-Flag antibody (red) and DAPI.  (B) C33A cells were 
cotransfected with VN-Brd4 and VC-16E2.  Forty-eight hours post transfection, cells 
were treated with 500 nM JQ1(-) or JQ1(+) for 1 hour.  The cells were then fixed and 
stained with anti-Flag antibody (red) and DAPI. Merge 1 is a merge of the BIFC and 
DAPI panels and Merge 2 is a merge of BIFC, FLAG and DAPI panels.  Bar, 5 μm.  The 
white arrow marks a BiFC focus superimposed on a mitotic chromosome. 
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CHAPTER 3:  Brd4 is Essential for HPV16 DNA 
Replication 
  
Research presented in this chapter was accomplished in collaboration with a 
postdoctoral fellow in our laboratory, Xin Wang, with equal contribution.  I have 
contributed to the experimental design, execution, and manuscript writing for the 
publication.  Together with Xin, I have examined the recruitment of Brd4 to the HPV 
replication foci by immunofluorescence (Figures 3.1-3.5) and tested Brd4 stimulation of 
HPV replication in vitro (Figure 3.6).  I have examined the association of the E2, E1, and 
Brd4 proteins by co-immunoprecipitation (Figures 3.2 and 3.5).  Xin performed the time 
course experiments (Figures 3.2 and 3.7), analyzed the viral genomes by immuno-FISH 
(Figure 3.3), and performed the in vivo replication experiments (Figures 3.5 and 3.7).  
Neha Pancholi offered feedback on the manuscript and provided technical assistance.  
James Bradner offered feedback on the manuscript and provided the JQ1(-) and JQ1(+) 
compounds.   
 
This research was originally published in Journal of Virology.  Xin Wang*, 
Christine M. Helfer*, Neha Pancholi, James E. Bradner, and Jianxin You.  Recruitment 
of Brd4 to the Human Papillomavirus Type 16 DNA Replication Complex is Essential 
for Replication of Viral DNA.  J. Virol. 2013 vol. 87(7) pp. 3871-3884. DOI: 
10.1128/JVI.03068-12.	   Copyright © American Society for Microbiology. *equal 
contribution 
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3.1:  Chapter Summary 
Replication of the HPV DNA genome relies on viral factors, E1 and E2, and the 
cellular replication machinery.  Brd4 interacts with E2 to mediate papillomavirus genome 
maintenance and viral transcription.  In this study, we examine the E2-Brd4 interaction in 
the presence of the HPV16 E1 protein and viral genome. We show that Brd4 is recruited 
to actively replicating HPV16 origin foci together with HPV16 E1, E2, and a number of 
the cellular replication factors: RPA70, RFC1, and DNA polymerase δ. Mutagenesis 
disrupting the E2-Brd4 interaction abolishes the formation of the HPV16 replication 
complex and impairs HPV16 DNA replication in cells. Brd4 is further demonstrated to be 
necessary for HPV16 viral DNA replication using a cell-free replication system in which 
Brd4 depletion by siRNA silencing leads to impaired HPV16 DNA replication whereas 
recombinant Brd4 protein is able to rescue viral DNA replication.  In addition, releasing 
endogenous Brd4 from cellular chromatin using the bromodomain inhibitor JQ1(+) 
enhances HPV16 DNA replication, demonstrating that the role of Brd4 in HPV DNA 
replication can be uncoupled from its function in chromatin-associated transcriptional 
regulation and cell cycle control.  This study reveals a new role for Brd4 in HPV genome 
replication, providing novel insights into understanding the life cycle of this oncogenic 
DNA virus. 
 
3.2:  Introduction 
Papillomavirus genome replication occurs during two different stages of the viral 
life cycle.  In the infected basal epithelial cells, the viral genome replicates an average of 
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once per cell cycle during S phase, in synchrony with the host DNA replication (65).  
This allows the viral genome to be maintained as stable episomes at 50 to 100 copies per 
cell.  This stage of DNA replication ensures a persistent infection in the basal layers of 
the epidermis.  Terminal differentiation of infected cells triggers vegetative viral DNA 
replication, producing viral genomes, which can then be assembled into virions and 
released from the surface of differentiated epithelium (74).   
The viral E1 and E2 proteins in combination with various components of the 
cellular DNA replication machinery carry out replication of the PV genome (74).  E2 
binds to several consensus E2 binding sites near the HPV origin of replication (Ori) and 
recruits E1 to the viral Ori (133, 221).  The cooperative binding of E1 and E2 proteins to 
the viral Ori form an E1-E2-Ori complex, in which E1 builds a hexameric ring around the 
viral DNA and functions as the helicase to unwind the HPV Ori for initiation of viral 
DNA replication (176).  For successful completion of the viral DNA replication, many 
components of the cellular replication machinery are recruited by E1 and E2 to the viral 
origin of replication.  For example, E1 has been shown to recruit the cellular DNA 
polymerase alpha/primase subunits to the viral replication origin (28, 122, 154).  E1 
interaction with the chaperone protein hsp40 and the single-stranded DNA-binding 
protein replication protein A (RPA) has also been shown to enhance E1 binding to the 
Ori and to facilitate processing of the replication fork, respectively (116, 118).  
Furthermore, interaction of E1 and hSNF5 proteins has been shown to stimulate HPV 
DNA replication (111). 
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  Brd4 is a critical host interacting partner for the PV E2 protein (224).  As 
presented in Chapter 2, Brd4 interacts with HPV16 E2 during interphase and mitosis and 
we and others have shown that Brd4 is an important factor in tethering the E2/viral 
genome complexes to host mitotic chromosomes to ensure faithful partitioning of 
replicated viral episomes to the nuclei of both daughter cells (Fig. 1.4, (17, 24, 75, 129, 
224)).  Brd4 also interacts with E2 to regulate viral transcription from the viral early 
promoter (see Chapter 4) (128, 174, 184, 216).   
Brd4 is primarily known for its role in cellular transcription where it recruits P-
TEFb to the pre-initiation complex (86, 223).  However, Brd4 has been shown to interact 
with the PCNA sliding clamp unloader, ATAD5, and replication factor C (RFC), 
suggesting that Brd4 plays a role in cellular DNA replication (83, 121, 163).  In 
accordance with Brd4’s role in DNA replication, a study from our laboratory discovered 
that Brd4 functions in Merkel cell polyomavirus (MCV) genome replication through 
interaction with MCV large T antigen (209).  HPV and MCV share similar properties in 
many aspects of their viral life cycles.  For example, the viral genomes of both HPV and 
MCV are maintained as circular double-stranded DNA episomes during latent infection. 
These viral genomes replicate poorly in monolayer cell cultures and both types of virions 
are commonly shed from healthy human skin surfaces.  In addition, MCV large T antigen 
and the HPV E1/E2 viral replication proteins are functionally conserved in binding the 
viral replication origin and interacting with Brd4.  Together, these observations suggest 
that Brd4 might also be important for HPV DNA replication.  In addition, Ilves et al. 
demonstrated that abrogation of the E2-Brd4 interaction reduces BPV1 genome 
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replication in some cell lines although the underlying mechanism was not fully 
investigated (82).  These observations prompted us to investigate the role of Brd4 in HPV 
replication. 
Here, we show that Brd4 is recruited to actively replicating HPV16 Ori foci 
together with HPV16 E1, E2, and a number of the cellular replication factors, including 
RPA70, RFC1, and DNA polymerase δ. The Brd4 function in HPV16 DNA replication 
was further demonstrated using several different approaches, including E2 mutagenesis, 
Brd4 silencing, and rescue of HPV16 replication in a cell-free replication system with 
recombinant Brd4 protein.  We also reveal that dissociating Brd4 from chromatin with 
the bromodomain inhibitor JQ1(+), stimulates HPV Ori replication. Together, our 
findings uncover a new role of Brd4 in HPV DNA replication that is distinct from its 
chromatin-associated transcriptional regulation function, providing novel insights into 
understanding the life cycle of this oncogenic DNA virus. 
	  
3.3:  Results 
3.3.1:  Brd4 colocalizes with E2 in large nuclear foci in the presence of HPV16 genomes 
Previous studies that examined the E2 and Brd4 interaction did so in the absence 
of other viral components such as the HPV genome and viral proteins.  In this study, we 
set out to investigate the interaction of Brd4 and HPV16 E2 in cells carrying the HPV16 
genome and E1 protein.  Interestingly, when C33A cells are transfected with HA-16E1, 
GFP-16E2 and the HPV16 genome, Brd4 is found colocalized in large, punctate dots 
with E2 (Fig. 3.1).  In contrast, in the absence of the HPV16 genome, exogenously 
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expressed GFP-16E2 is diffuse as reported previously (170, 193), while Brd4 staining 
gives a characteristic speckled pattern in the nucleus (Fig. 3.1). This suggests that the 
HPV16 genome can enrich the interaction and colocalization of Brd4 and HPV16 E2 into 
subnuclear domains and/or promote the recruitment of the HPV16 E2/Brd4 complex to 
the HPV16 replication centers.  This intriguing result prompted us to further investigate 
the potential function of the E2-Brd4 interaction in HPV16 replication.  
3.3.2:  HPV16 E1, E2, and Brd4 are recruited to the viral Ori replication foci.  
The HPV16 genome contains the viral upstream regulatory region (URR), which 
includes transcription regulatory elements and the viral DNA replication origin.  HPV E2 
initiates viral gene transcription by recruiting many transcription factors, including Brd4, 
to the URR (86, 96, 101, 108-110, 223).  The data shown in Fig. 3.1 suggests that Brd4 
might be recruited by E2 to the viral URR to contribute to E2 viral transcription and/or 
replication function.  Additionally, Brd4 might simply be enriched at the HPV16 genome 
through the binding of acetylated histones on HPV minichromosomes (138).  To set up a 
system that would allow us to specifically examine the function of Brd4 in HPV16 
replication instead of viral transcription and minichromosome association, we constructed 
an artificial episome that contains the 145 base pair minimum HPV replication Ori (Fig. 
3.2 A), which we termed pHPVOri.  This episome excludes most of the URR 
transcription regulatory elements, such as the binding sites for C/EBP, NF1, OCT-1, and 
the TATA box of the viral early promoter, retaining only three E2 binding sites (E2BS), 
one E1 binding site (E1BS), a GT-1 binding site, and an SP1 binding site (Fig. 3.2 A).  
According to mutagenesis studies performed in HPV11 URR, neither GT-1 site nor SP1 
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site deletion dramatically affects viral early promoter activities, suggesting that these sites 
might not contribute significantly to the early promoter transcription (230).  Therefore, 
this plasmid with the minimum HPV16 Ori allows us to separate the HPV16 E2 
transcription and replication functions and to specifically examine the recruitment of 
Brd4 and its impact on HPV16 replication. 
Using the pHPVOri plasmid, we observed a similar phenomenon as seen in Fig. 
3.1 with E2 and Brd4 colocalized in large foci only in the cells cotransfected with 
pHPVOri, E1 and, E2 constructs (data not shown).  To visualize cells transfected with the 
HPV16 Ori construct and to also study the foci formation in the presence of HPV16 E1 
protein, we inserted an HA-16E1 expression cassette, which includes HA-tagged 16E1 
under the control of a CMV promoter, in pHPVOri to generate the pHPVOri/E1 plasmid 
(Fig. 3.2 A).  With this plasmid, HPV16 Ori-positive cells can be identified as those 
stained positive for HA-16E1.   
 During HPV genome replication, E2 binds to its binding sites in HPV16 Ori and 
recruits E1 and cellular replication factors to the viral DNA replication complex (27, 199-
201).  To monitor the localization pattern of Brd4, E1, and E2 in cells carrying HPV16 
Ori, cells transfected with GFP-16E2 and pHPVOri/E1 were stained by IF in three colors 
to show Brd4 in red, E1 in blue, and E2 displaying GFP green fluorescence.  In these 
cells, we detected a clear colocalization pattern of Brd4, E2, and E1 assembled into large 
foci in 55.1% ± 3.4% of E1 and E2 double-positive cells (Fig. 3.2 B, experiment n ≥ 3).  
The formation of Brd4-E1-E2 foci requires the HPV16 Ori because in cells transfected 
with GFP-16E2 and HA-16E1, which does not carry the HPV16 Ori, both E1 and E2 
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staining are diffuse in the nucleus of most cells and in only 19.8% ± 1.5% of E1 and E2 
double positive cells, the viral proteins colocalize as tiny dots (Fig. 3.2 B, experiment n ≥ 
3). This phenomenon was also reported in a previous study (170).  Interestingly, in these 
cells, Brd4 staining is markedly altered from its normal punctate pattern to a more diffuse 
pattern that only partially colocalizes with the tiny E1/E2 dots (Fig. 3.2 B).  In cells 
transfected with GFP-16E2 and HPVOri that does not carry the E1 expression cassette, 
E2 staining is diffuse despite the presence of HPVOri, while Brd4 maintains its usual 
speckled pattern (Fig. 3.2 B). This result is surprising because we expected E2 to bind the 
E2BSs within the Ori plasmid and to recruit Brd4.  However, Brd4 was recruited to the 
large foci only when E1, E2, and HPV16 Ori were all present (Fig. 3.2 B). This 
observation suggests that E1 plays an important role in building these foci and recruiting 
Brd4.  Together, these results indicate that recruitment of Brd4 into the large nuclear foci 
is dependent on the formation of the intact E1-E2-Ori replication complex.   We also 
performed a time course experiment to look at the kinetics of viral replication focus 
formation over time (Fig. 3.2 C).  Smaller Brd4, E1, and E2 replication foci were 
observed at earlier times post transfection.  The size of the replication foci as detected by 
E1 staining continued to increase after 12 hours post transfection and reached a plateau at 
36 hours post transfection.    
The Brd4/E2/E1 complex was further investigated by Brd4 immunoprecipitation 
using cells transfected with CMV-Flag16E2 and either empty vector or HA-16E1.  
Consistent with previous findings, Brd4 is able to interact with and pull-down E2 (Fig. 
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3.2 D).  Interestingly, E1 was also pulled-down with E2 and Brd4 providing biochemical 
evidence that these proteins assemble into a complex. 
3.3.3:  Brd4 colocalizes with the HPV16 DNA replication complex 
Previous studies show that the E1 and E2 proteins co-expressed in cells localize to 
defined nuclear foci and induce a cellular DNA damage response (137, 170).  To rule out 
the possibility that the E1, E2, and Brd4 foci observed in this study are sites of host 
chromosomal DNA replication and to demonstrate that these foci contain the HPV Ori, 
immuno-FISH was performed.  C33A cells cotransfected with E2 and pHPVOri/E1 were 
examined by immunofluorescence to detect the viral proteins and by FISH to detect the 
HPV16 Ori.  FISH using HPV16 Ori-specific probes detected large foci of HPV16 Ori 
similar to those detected by IF as shown in Fig. 3.2 B, while no signal was detectable 
when non-specific probes targeting the MCV genome were used (Fig. 3.3 A, B).  In 
addition, both E1 and E2 colocalized with the HPV16 Ori in large nuclear foci in nearly 
all cells carrying viral replication foci (Fig. 3.3 A, B).  Brd4 was also detected in these 
foci containing the HPV16 Ori (data not shown).  These results further demonstrate that 
the large nuclear foci containing E1, E2, and Brd4 are centered on the HPV16 Ori.  
Since the HPV16 foci we observed contain the viral replication proteins, E1 and 
E2, and the HPV16 Ori, we next determined if these foci are centers of viral replication. 
To test this, C33A cells cotransfected with GFP-16E2 and various vectors carrying 16E1 
and/or Ori were pulse labeled with BrdU to detect its incorporation into newly 
synthesized DNA.  As shown in Fig. 3.3 C, in cells transfected with GFP-16E2 and 
HPV16 Ori, GFP-16E2 and BrdU staining was diffuse in the nucleus and Brd4 was in its 
63 
	  
normal nuclear speckled pattern. Cells transfected with pHPVOri/E1 and the empty GFP 
vector, pEGFPC1, also displayed a background BrdU staining and the normal speckled 
Brd4 pattern, while most of the GFP protein was removed by the acetone fixation used in 
the BrdU staining (Fig. 3.3 C).  The diffuse BrdU staining in these cells cotransfected 
with HPV16 Ori and either E1 or E2 alone indicates that they do not have active HPV16 
Ori replication (Fig. 3.3 C).  Since these cells also have unaltered Brd4 localization 
pattern, the result suggests that both E1 and E2 are needed to support viral replication and 
Brd4 recruitment.  In accordance with this notion, cells cotransfected with GFP-16E2 and 
pHPVOri/E1 displayed clear colocalization of GFP-16E2 and BrdU in large HPV16 Ori 
foci in 82% ± 8.8% of transfected cells (Fig. 3.3 C, experiment n = 3).  Interestingly, 
Brd4 and E1 were also clearly present in the BrdU-labeled foci with E2 in these cells 
(Fig. 3.3 C and data not shown).  It was clear that formation of these large foci is 
dependent on HPV16 Ori, since 54% ± 11.1% of cells transfected with GFP-16E2 and 
HA-16E1 that do not carry HPV16 Ori had small nuclear dots with GFP-16E2, Brd4 and 
BrdU colocalized while the rest of the cells had diffuse GFP-16E2 staining in the nucleus 
(Fig. 3.3 C, experiment n = 3).  This result is consistent with previous reports showing 
that E1 and E2 can form small foci that colocalize with BrdU and cellular replication 
factors on host chromatin (170, 193).  The small foci formed in the absence of HPV16 
Ori are likely sites of E1- and E2-mediated non-specific unwinding/replication on the 
cellular genome.  Our results demonstrate that Brd4 and the HPV replication proteins are 
present together at the HPV Ori in active viral replication compartments and suggest that 
Brd4 might be involved in HPV replication.  
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HPV genome replication requires the cellular replication machinery and it has 
previously been shown that host replication factors are recruited to HPV replication 
compartments (170, 193).  To further demonstrate that the large Brd4-E2-E1 foci are 
viral replication centers, we next determined if host replication proteins are recruited to 
these foci.  For this, C33A cells cotransfected with Flag-16E2 or GFP-16E2 and various 
vectors carrying 16E1 and/or Ori were immunostained for the RPA component, RPA70, 
replication factor C1 (RFC1), or DNA polymerase δ.  As shown in Fig. 3.4, cells 
transfected with both E2 and pHPVOri/E1 had large E2-positive nuclear foci, which 
colocalized with all three replication proteins tested.  RPA70 was observed colocalized 
with large foci in 67% ± 7.8% of cells while RFC1 and DNA polymerase δ colocalized 
with large foci in 51% ± 5.8% and 57.5% ± 2.7% of transfected cells respectively.  In the 
absence of HPV16 Ori, E2 and E1 formed small foci that only partially colocalized with 
RPA70 and RFC1 in 61% ± 0.8% and 32% ± 4.9% of transfected cells, respectively (Fig. 
3.4 A and B, experiment n = 3). DNA polymerase δ did not localize to the small foci and 
was diffuse in the nucleus without HPV Ori (Fig. 3.4 C, experiment n = 3). Without E1, 
E2 cotransfected with the HPV16 Ori construct did not form nuclear foci, and all three 
replication factors remained diffuse (Fig. 3.4). These results offer additional support that 
the large foci formed in cells transfected with both E2 and pHPVOri/E1 are sites of HPV 
DNA replication.  The fact that Brd4 colocalizes with these replication factors in the 
HPV16 Ori foci provides further support for its role in HPV16 replication. 
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3.3.4:  Brd4 is important for transient HPV16 replication in cells 
Since Brd4 is clearly recruited to the HPV replication Ori foci that are actively 
replicating, we further investigated the role of the Brd4-E2 interaction in HPV16 DNA 
replication using HPV16 E2 mutant R37A/I73A, which is unable to interact with Brd4. 
As observed before, in cells transfected with wild type E2 and pHPVOri/E1, large foci 
were found in 56.9% ± 5.1% of E2-positive cells (Fig. 3.5 A, experiment n = 3). 
Conversely, when the E2-Brd4 interaction was abolished with E2 R37A/I73A mutations, 
large foci or tiny dots were found in <10% of cells and most cells had diffuse staining of 
E2, E1, and Brd4 (Fig. 3.5 A and data not shown, experiment n = 3). In the few cells with 
E1/E2 foci, Brd4 staining was more diffuse and only partially colocalized with the foci.  
Because large HPV replication foci cannot be efficiently formed in the E2 R37A/I73A 
cells, this set of results suggested that the E2-Brd4 interaction is essential for recruitment 
of Brd4 and formation of the HPV16 Ori replication foci. We also studied the E2 E39A 
mutant, which does not interact with E1 and, therefore, does not support HPV replication.  
As was predicted, cells transfected with both E2 E39A mutant and pHPVOri/E1 were not 
able to support large HPV replication foci formation as in the cells containing wild type 
E2 (Fig. 3.5 A). This result confirms that the E1 and E2 interaction is important for the 
formation of HPV replication foci.  Interestingly, this E2 E39A mutant did not 
completely eliminate E1/E2 colocalization since, in 26.3% ± 3.5% of the transfected 
cells, E1, E2, and Brd4 were observed to colocalize in tiny dots (Fig. 3.5 A, experiment n 
= 3).  However, these foci are much smaller than those observed in wild type E2 
transfected cells.  It is possible that, while the E2 E39A mutant failed to recruit E1 to 
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form the large HPV Ori replication complexes, E1 can still bind to the HPV Ori in an E2-
independent manner to form the small foci as has been previously described (39).  Brd4 is 
recruited in these small foci presumably through binding to the E2 E39A mutant. We also 
examined the E2 R302K and R304K mutants, which do not interact with DNA but retain 
Brd4 binding (26), for their ability to form replication foci.  Similar to the E39A mutant, 
in cells transfected with pHPVOri/E1 and E2 R302K or R304K, 35.2% had tiny dots 
while the rest had diffuse staining of E2, E1, and Brd4 (Fig. 3.5 A and data not shown).  
Large replication foci were not found with these DNA binding-deficient mutants.  From 
these results it seems that both the E2-Brd4 and E2-E1 interactions and E2-DNA binding 
are necessary for the formation of large HPV replication foci, suggesting that these 
interactions are important for viral replication.   
  To further analyze the impact of the E2-Brd4 and E1-E2 interactions on HPV16 
Ori DNA replication, we performed an in vivo replication assay comparing various E2 
mutants with wild type E2.  C33A cells were transfected with pHPVOri/E1 and the E2 
constructs indicated in Fig. 3.5 B.  Episomal DNA was collected at 6 and 48 hours post 
transfection for Southern blot analysis.  The 6-hour DNA samples, which served as 
transfection controls, showed that transfection efficiencies were similar, and an equal 
amount of the initial viral DNA template was loaded for each lane (Fig. 3.5 B). Western 
blot analysis showed that E1 and the various E2 constructs were also expressed in cells at 
comparable levels (Fig. 3.5 C).  For analysis of newly synthesized HPV16 Ori, the DNA 
samples collected at 48 hours post transfection were digested with XhoI to linearize the 
plasmid and with DpnI to remove input plasmid.  As shown in Fig. 3.5 B, cells 
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transfected with wild type E2 supported efficient replication of HPVOri.  This HPVOri 
replication was dependent on E2, as cells transfected with empty vector did not replicate 
the HPV16 Ori plasmid.  As expected, the E2 E39A mutant with abrogated E1-E2 
interaction was nearly completely impaired in HPV16 Ori replication.  More importantly, 
the E2 R37A/I73A double mutations, which disrupt the E2-Brd4 interaction, also 
significantly reduced HPV16 Ori replication (Fig. 3.5 B, P<0.05, n=3).  Co-
immunoprecipitation analysis showed that the E2 R37A/I73A double mutant interacts 
with 16E1 similarly to wild type 16E2 (Fig. 3.5 D) suggesting that its reduced DNA 
replication activity is not caused by a defect in E1 binding.  We previously showed that 
the 16E2 R37A/I73A double mutant retains low-level binding to Brd4 (Fig. 2.2), which 
could explain why this double mutant still maintains some replication activation activity.  
Notably, the E2 single mutants, R37A and I73A, could replicate HPV16 Ori slightly 
better than the R37A/I73A double mutant (Fig. 3.5 B).  The partial inhibition of the 
HPV16 replication by these two single mutants, especially R37A, has been reported in a 
previous study using detailed structure-function analysis to separate the transcriptional 
activation and replication activities of HPV16 E2 (168).  We suspect the single mutants 
can support a little more HPVOri replication than the E2 R37A/I73A mutant because 
they likely retain even more interactions with Brd4 than the E2 R37A/I73A double 
mutant. Together, these results suggest that the E2-Brd4 interaction is necessary for 
HPV16 Ori replication.  
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3.3.5:  Brd4 is important for HPV DNA replication in vitro 
Brd4 plays an important role in regulating host gene transcription and cellular 
growth (222).  Brd4 knockdown could therefore induce cell cycle arrest, which would 
indirectly inhibit HPV DNA replication. This prevented us from using Brd4 silencing as a 
fair approach to test the functional role of Brd4 in HPV DNA replication in cells.  To 
overcome this problem, we set up a cell-free replication system as an alternative strategy. 
In the in vitro replication assay, protein lysates to be used as a source of replication 
factors were isolated from cells transfected with HPV16 E1 and E2 proteins and either 
non-targeting control siRNA or Brd4 specific siRNA (Fig. 3.6).  These lysates were 
mixed with the HPV16 genome template and in vitro replication components to set up the 
reaction (see details in Materials and Methods). As shown in Fig. 3.6 A, lysates from 
cells expressing both E1 and E2 boosted HPV16 viral DNA synthesis by more than 12-
fold compared to the cell lysates without E1 and E2 (compare CO lanes to No E1/E2 
lane), although a low level of E1/E2-independent viral DNA synthesis was detected in the 
No E1/E2 lysate.  Compared with reactions using control siRNA-transfected C33A cells, 
Brd4 knockdown cell lysates showed a more than 3-fold reduction in HPV16 DNA 
replication in vitro (Fig. 3.6 A, n=3).  This is not likely due to a change in the viral 
protein expression because E1 and E2 expression was not affected by Brd4 knockdown 
(Fig. 3.6 D).  This result suggests that Brd4 might directly contribute to HPV16 DNA 
replication.  
To demonstrate that this reduction of HPV16 DNA replication in Brd4 
knockdown cell lysates was not due to cell cycle arrest caused by Brd4 knockdown, 
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recombinant Brd4 expressed and purified from insect cells was added to replication 
reactions to restore Brd4 levels (Fig. 3.6 E).  Compared to the control, addition of 
recombinant Brd4 increased the HPV16 genome replication by about 2.8-fold (Fig. 3.6 A, 
compare rBrd4 lanes with Control lanes, n=3).  In contrast, rBrd4 did not increase 
HPV16 replication when cellular Brd4 was not depleted (Fig. 3.6 A).  The recombinant 
Brd4 also rescued in vitro HPV16 genome replication in Brd4 knockdown cell lysates in 
a dose-dependent manner, causing about a 7-fold increase in HPV16 DNA replication 
(Fig. 3.6 B, compare 2 μg lanes to KD lanes, n=3).  Moreover, recombinant Brd4 purified 
from E. coli could also restore HPV16 replication in Brd4 knockdown lysates (data not 
shown).   
Since E1 protein of HPV1a is sufficient to initiate viral DNA replication (68) and 
the Brd4 CTD, which can block the E2-Brd4 interaction, does not significantly inhibit 
HPV16 replication in C33A cells (82, 174), we investigated if the Brd4 activity in 
HPV16 replication is solely dependent on its interaction with E2.  In the in vitro 
replication assay using cellular extracts containing 16E1 but not 16E2, HPV16 replication 
could be detected in the control siRNA-treated samples and was also inhibited upon Brd4 
knockdown (Fig. 3.6 C, F).  rBrd4 could partially restore the 16E1-mediated HPV16 
replication (Fig. 3.6 C).  However, rBrd4 was able to more efficiently stimulate the viral 
replication in the reaction mixtures containing both E1 and E2 (compare the 
quantification data in Fig. 3.6 B and C), suggesting that the E2-Brd4 interaction is 
important for the viral DNA replication in vitro.  Together, the results shown in Fig. 3.6 
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demonstrate that Brd4 stimulates HPV16 DNA replication in vitro and is directly 
associated with HPV16 DNA replication. 
3.3.6:  Release of endogenous Brd4 from chromatin stimulates HPV16 DNA replication  
Most of Brd4’s cellular functions are associated with its chromatin localization 
through a dynamic “on and off” interaction with acetylated histones (36).  Since Brd4 can 
relocate from cellular chromatin to the HPV16 Ori replication complex, we postulated 
that releasing Brd4 from chromatin might facilitate HPV16 DNA replication.  The 
chemical compound, JQ1(+), provides an excellent tool to test this possibility because it 
can prevent the binding of Brd4 to tetra-acetylated histone H4 peptides (51).  We decided 
to test whether release of Brd4 from chromatin using JQ1(+) affects HPV16 Ori DNA 
replication.  Brd4 binds acetylated chromatin and is normally observed in a nuclear 
speckled pattern in C33A cells (75).  Treating C33A cells with 300 nM JQ1(+) could 
efficiently alter Brd4 localization from punctate foci on chromatin to a dimmer and more 
diffuse pattern throughout the nucleus, indicating the release of endogenous Brd4 from 
chromatin (Fig. 3.7 A).  Lower concentrations of JQ1(+) only slightly released Brd4 from 
chromatin while the inactive stereoisomer, JQ1(-), or DMSO vehicle control did not 
noticeably affect Brd4 staining in C33A cells (Fig. 3.7 A).  To determine if JQ1(+) could 
affect HPV16 DNA replication, pHPVOri/E1 and E2 cotransfected cells were split into 
five dishes and each treated with 100, 200, and 300 nM JQ1(+), 300 nM JQ1(-), or an 
equal volume of DMSO.  The extracted episomal DNA samples were digested with both 
DpnI and XhoI and used in Southern blotting to analyze the HPV16 Ori replication 
product, whereas the samples without DpnI digestion were used as loading control. As 
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shown in Fig. 3.7 B, 300 nM JQ1(+) treatment, which efficiently releases Brd4 from 
chromatin, increased HPV16 Ori replication while the other drug concentrations had little 
effect. Treatment with 300 nM JQ1(+) did not affect E2 expression but slightly increased 
E1 expression likely due to stimulation of pHPVOri/E1 DNA replication in these cells 
(Fig. 3.7 B).   JQ1(+) also stimulated HPV replication in cells carrying Ori and E1 
encoded by two separate plasmids, HPVOri and HA-16E1, cotransfected with CMV4-
Flag-16E2 (data not shown), further supporting a direct role of JQ1(+) in stimulating the 
viral DNA replication.  Using flow cytometry analysis, we confirmed that 300 nM 
JQ1(+) treatment does not cause cell cycle arrest (Fig. 3.7 C, experiment n = 3), 
suggesting that the induced HPV16 Ori DNA replication was not caused by a cell cycle 
effect associated with JQ1(+) treatment.  We also examined how JQ1(+) affects the 
kinetics of HPV16 replication focus formation by monitoring BrdU incorporation over 
time.  Compared to DMSO-treated cells, JQ1(+) treatment leads to increased BrdU focus 
size during the early time points and the percentage of large BrdU replication foci 
throughout the experiment (Fig. 3.7 D).  These results suggest that the release of Brd4 
from cellular chromatin stimulates HPV16 DNA replication, likely by relocating Brd4 to 
the HPV16 Ori replication complex. The data also demonstrate that the role of Brd4 in 
HPV DNA replication could be uncoupled from its cell cycle and transcriptional 
regulation function.  
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3.4:  Discussion 
 In this study we discovered a novel role for Brd4 in HPV genome replication.  
Brd4 was found colocalized with the HPV replication factors, E1 and E2, and the viral 
genome in actively replicating viral foci.  It was further demonstrated that the E2-Brd4 
interaction is necessary for formation of these replication foci and for efficient HPV 
genome replication in vivo.  We also showed that cellular lysates depleted of Brd4 do not 
support HPV in vitro replication while purified Brd4 protein can restore replication in 
these lysates.  Finally, we provide evidence that release of Brd4 from cellular chromatin 
enhances HPV DNA replication. 
 While our data demonstrate an important role of Brd4 in HPV DNA replication, 
Brd4’s specific function during viral replication is still unknown.  Brd4 is known to 
interact with cellular replication factors including RFC1 and ATAD5 (83, 121, 163) and 
our laboratory previously showed that Brd4 functions in Merkel cell polyomavirus 
replication by recruiting RFC1 to MCV replication foci (209).  We can detect both RFC1 
and ATAD5 in HPV replication centers (data not shown) so it is possible that, similar to 
MCV, Brd4 functions in HPV replication to recruit specific cellular replication proteins 
to the viral foci.  Our finding that release of Brd4 from chromatin promotes HPV DNA 
replication might support this hypothesis since Brd4 removal from chromatin could make 
Brd4 more free and accessible to bind and recruit replication proteins to viral replication 
centers.  Further studies are needed to address this possible role of Brd4 in replication 
factor recruitment. 
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Sakakibara et al. also examined Brd4 function during HPV genome replication 
and were able to detect Brd4 in small, newly formed viral replication foci but showed 
Brd4 was displaced from larger, mature foci (169). This finding differs from our results 
most likely because of the different cell types used in the two studies; primary human 
keratinocytes were used in their study while our experiments used a cervical cancer cell 
line.  Nevertheless, this finding supports the theory that Brd4 is required for the early 
formation of replication centers.  This study also demonstrated that Brd4 is associated 
with early replication foci but is displaced once the replication foci mature.  In support of 
our observation that Brd4 release from chromatin stimulates HPV DNA replication, this 
result suggests that for efficient viral genome amplification, the replication centers need 
to detatch from cellular chromatin along with Brd4, which might explain why they 
observed both Brd4 and acetylated host chromatin displaced from mature replication foci.  
Since our data was from experiments using a transformed cell line and the experiments 
presented in Sakakibara et al. were mostly qualitative immunofluorescent analyses of 
Brd4 colocalization in replication foci, future experiments should focus on utilizing 
functional replication assays to determine whether Brd4 is important for HPV replication 
in naturally HPV infected cells. 
HPV is often found integrated into common fragile sites in HPV-associated 
cancers (31, 123, 186, 195, 196).  Common fragile sites are stretches of the genome that 
are highly prone to DNA damage and replication stress (56).  Since these regions are 
frequently sites of DNA damage repair and papillomaviruses have been shown to co-opt 
cellular DNA damage response (DDR) proteins for viral genome amplification (137, 
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170), we and others speculate that HPV replication centers might localize near common 
fragile sites to access the DDR proteins (169).  Intriguingly, a recent report demonstrated 
that Brd4 binds chromatin near common fragile sites and recruits HPV replication 
complexes to these sites to facilitate viral replication (87).  In light of this finding, it is 
unclear why Brd4 seems to be eventually displaced from HPV replication foci and why 
JQ1(+) treatment stimulates viral replication.  Obviously further studies are needed to 
address these questions in order to fully understand Brd4’s function in papillomavirus 
genome replication. 
The interesting results obtained from the JQ1(+) studies presented here and in 
chapters 2 and 4 suggest that this chemical compound could be a valuable tool to 
eliminate HPV infection as it can release Brd4 from chromatin and abrogate viral 
episome maintenance and viral gene transcription.  More importantly, since HPV genome 
amplification normally occurs exclusively in terminally differentiated cells to avoid 
detection by host immune surveillance, an impromptu viral genome amplification 
induced by JQ1(+) in the infected basal cells could trigger activation of the immune 
response to clear the viral latent infection before cancer development.  This small 
molecule therefore offers a promising lead for development of antiviral inhibitors to treat 
HPV latent infection. 
3.5:  Figures 
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Figure 3.1 
 
 
 
 
Figure 3.1. Brd4 and HPV16 E2 colocalize in punctate nuclear foci only in the 
presence of HPV16 genome.  C33A cells were cotransfected with pUC19-HPV16, GFP-
16E2, and HA-16E1.  The pUC19-HPV16 plasmid was replaced by pUC19 in the 
“without HPV16 genome” transfection control.  At 48 hours post transfection, cells were 
fixed and stained using anti-Brd4 antibody and counterstained with DAPI.  Bar, 5 μm. 
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Figure 3.2 
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Figure 3.2. Brd4 and HPV16 E2 colocalization in nuclear foci is dependent on both 
HPV E1 and viral origin.  (A) Schematic diagram of the artificial pHPVOri/E1 
episome.  E1BS, E1 binding site. E2BS, E2 binding site. P97, TATA box of viral early 
promoter. GT-1, transcription factor GT-1.  Sp1, specificity protein 1. (B) C33A cells 
were cotransfected with GFP-16E2 and either pHPVOri/E1, HA-16E1, or HPVOri.  At 
60 hours post transfection, cells were fixed and co-stained using anti-Brd4 (red) and anti-
HA (blue) antibodies.  Bar, 5 µm.  (C) C33A cells were cotransfected with GFP-16E2 
and HPVOri/E1 and co-stained as in panel B at 12, 18, 24, 36, and 48 hours post 
transfection.  Foci with an area larger than this mean value were considered big foci.  The 
mean area of these big foci (numbers in black) and the percentage of big foci in total foci 
(numbers in red) were calculated for each time point and are shown at the top of each 
column.  (D) C33A cells were cotransfected with CMV4-Flag16E2 and either empty 
vector (V) or HA-16E1 (E1).  At 48 hours post transfection, nuclear proteins were 
harvested and immunoprecipitated with the indicated antibodies. The precipitates were 
immunoblotted with specific antibodies as indicated.   
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Figure 3.3 
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Figure 3.3. Brd4 colocalizes with HPV16 E1 and E2 proteins in foci harboring 
actively replicating HPV episomes. (A and B) C33A cells were cotransfected with 
pHPVOri/E1 and CMV4-Flag16E2.  At 48 hours post transfection, biotin-labeled probes 
targeting pHPVOri/E1 (Specific Probe) were used to detect the replicating DNA while 
probes targeting Merkel cell polyomavirus genome (Non-Specific Probe) were used as a 
non-specific control.  HPV16 E1 (A) and E2 (B) were stained using anti-HA and anti-
Flag antibody, respectively. The cells were also counterstained with DAPI.  Bar, 5 μm. 
(C) C33A cells were cotransfected with GFP-16E2 or pEGFPC1 and either pHPVOri/E1, 
HA-16E1, or HPVOri. At 42 hours post transfection, the cells were labeled with BrdU for 
twenty minutes and grown for an additional hour prior to acetone fixation. Cells were 
immunostained for Brd4 (blue) and BrdU (red). Bar, 5 μm. 
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Figure 3.4  
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Figure 3.4. Host replication factors are recruited to the HPV16 E1/E2 foci in a HPV 
origin-dependent manner.  (A and B) C33A cells were cotransfected with Flag-16E2 
expression vector and either pHPVOri/E1, HA-16E1, or HPVOri.  At 48 hours post 
transfection, the cells were fixed and immunostained for E2 (α-Flag; green) and RPA70 
(red) (A) or RFC1 (red) (B).  The cells were also counterstained with DAPI.  (C) C33A 
cells were cotransfected with GFP-16E2 and either pHPVOri/E1, HA-16E1, or pHPVOri. 
At 64 hours post transfection, cells were fixed and co-stained with anti-DNA polymerase 
δ (red) and anti-HA (blue) antibodies. Bar, 5 μm. 
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Figure 3.5 
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Figure 3.5. The Brd4-E2 interaction is important for HPV16 replication.  (A) C33A 
cells were cotransfected with pHPVOri/E1 and the GFP-16E2 construct indicated in the 
right panel.  At 48 hours post transfection, cells were fixed and co-stained with anti-Brd4 
(red) and anti-HA (blue) antibodies.  (B) C33A cells were cotransfected with 
pHPVOri/E1 and either CMV4 (Vector) or the CMV-Flag-16E2 construct indicated in 
(B). Episomal DNA was extracted at 6 hours post transfection for transfection controls 
and 48 hours post transfection for newly synthesized DNA.  These were digested with 
XhoI or XhoI/DpnI respectively, and analyzed by Southern blotting.  The intensity of 
each replicated DNA band was quantified by ImageJ and normalized to E2wt.  (C) Cells 
were transfected as in (B).  At 48 hours post transfection, extracted protein was analyzed 
by Western blotting using anti-16E2 and anti-HA antibodies.  (D) C33A cells were 
cotransfected with HA-16E1 and either CMV4 (Vector), CMV4-Flag-16E2 wild type, or 
CMV4-Flag-16E2 R37A/I73A.  Cell lysates were immunoprecipitated with anti-Flag 
antibody.  The precipitates were immunoblotted with specific antibodies as indicated. 
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Figure 3.6 
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Figure 3.6. Brd4 directly stimulates HPV16 replication in vitro.  (A) C33A cells were 
transfected with siRNA targeting Brd4 (KD) or nontargeting control siRNA (CO).  At 36 
hours post transfection, cells were transfected with pOZN-16E2 and HA-16E1.  Cell 
extracts were prepared at 82 hours post transfection for the in vitro replication assay 
using religated HPV16 genomes as the template.  Cells transfected with the nontargeting 
siRNA but not the E1/E2 constructs were used as a negative control (no E1/E2). In the 
“rBrd4” reaction, 2 μg rBrd4 expressed and purified from Sf9 insect cells was added to 
the replication assays with Brd4 knockdown extract to restore HPV16 replication.  In the 
“Control” condition, an equal amount of non-specific proteins isolated from the wild type 
baculovirus-infected Sf9 cells were used.  The intensity of each replicated DNA band was 
quantified by ImageJ and normalized to one of the control replicates. (B) Cell extracts 
and rBrd4 were prepared as in (A).  Increasing amounts of rBrd4 was added to the 
replication assays using Brd4 knockdown extracts. The intensity of each replicated DNA 
band was quantified by ImageJ and normalized to one of the control replicates. (C) Cell 
extracts were prepared as in (A) except at 36 hours post transfection, cells were 
transfected with only HA-16E1.  Cells transfected with the nontargeting siRNA but not 
the E1 construct were used as a negative control (no E1).  Increasing amounts of rBrd4 
purified from insect cells were added to the replication assays using Brd4 knockdown 
extracts.  The intensity of each replicated DNA band was quantified by ImageJ and 
normalized to one of the control replicates. (D) Western blot analysis of the HPV16 E1, 
E2, and Brd4 proteins in cellular extracts used for in vitro replication.  (E) Coomassie 
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brilliant blue staining of rBrd4 purified from insect cells.  (F) Western blot analysis of the 
HPV16 E1 and Brd4 proteins in cellular extracts used in panel (C). 
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Figure 3.7 
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Figure 3.7. Releasing Brd4 from chromatin by JQ1(+) increases HPV16 replication. 
(A) C33A cells were treated with JQ1(+), JQ1(-), or DMSO at the indicated 
concentrations for 24 hours. Cells were then fixed and immunostained with anti-Brd4 
antibody and counterstained with DAPI. Bar, 5 μm. (B) C33A cells transfected with 
pHPVOri/E1 and CMV4-Flag16E2 were split equally into 6 dishes. Cells were treated 
with 100, 200, 300 nM JQ1(+), 300 nM JQ1(-), or an equal volume of DMSO. At 48 
hours post transfection, episomal DNA was extracted, digested with DpnI and XhoI, and 
600 ng was used to analyze the replication product while 2.5 ng XhoI treated DNA was 
used as loading control in a Southern blot. Cellular extracts were analyzed by Western 
blotting using anti-16E2, anti-HA, and anti-actin antibodies. NTC, non-transfection 
control. (C) C33A cells were treated as described in (A).  Flow cytometry analysis was 
performed to evaluate the impact of JQ1(+) treatments on the cell cycle.  (D) C33A cells 
were transfected as in (B) and treated with DMSO or 300 nM JQ1(+).  Cells were labeled 
using BrdU as in Figure 3.3 C and co-stained with anti-HA E1 and anti-BrdU antibodies 
at 12, 18, 24, 36, and 48 hours post transfection.  The area of BrdU foci was quantified 
for about 30 cells from each sample using ImageJ.  The red dashed line represents the 
mean area of BrdU foci in the DMSO-treated sample at 48 hours post transfection.  Foci 
with an area larger than the mean value were considered big foci.  The mean area of these 
big foci (numbers in black) and the percentage of big foci in total foci (numbers in red) 
were calculated for each time point and are shown at the top of each column. 
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CHAPTER 4:  Brd4 has Multiple Functions in E2-
Mediated Papillomavirus Transcription 
Activation 
 
 
I was the principal researcher that designed and performed the experiments in this 
chapter.  A former postdoctoral fellow in our laboratory, Junpeng Yan, performed some 
preliminary experiments that initially got us interested in this project.  Junpeng also 
cloned some of the DNA constructs used in this work.  
	  
	  
	  
	  
 
 
 
The manuscript presenting this research has been submitted to Viruses.  Christine 
M. Helfer, Junpeng Yan, and Jianxin You.  The Cellular Bromodomain Protein Brd4 has 
Multiple Functions in E2-Mediated Papillomavirus Transcription Activation.  Submitted 
May 26, 2014. 
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4.1:  Chapter Summary 
The cellular bromodomain protein Brd4 functions in multiple processes of the 
papillomavirus life cycle including viral replication, genome maintenance, and gene 
transcription through its interaction with the viral protein, E2.  However, the mechanisms 
by which E2 and Brd4 activate viral transcription are still not completely understood.  In 
this study, we show that recruitment of P-TEFb, a functional interaction partner of Brd4 
in transcription activation, is important for E2’s transcription activation function.  
Furthermore, chromatin immunoprecipitation (ChIP) analyses demonstrate that P-TEFb 
is recruited to the native papillomavirus episomes.  We also show that E2’s interaction 
with cellular chromatin through Brd4 correlates with its papillomavirus transcription 
activation function since JQ1(+), a bromodomain inhibitor that efficiently dissociates E2-
Brd4 complexes from chromatin, potently represses papillomavirus transcription.  Our 
study identifies a specific function of Brd4 in papillomavirus gene transcription and 
highlights the potential use of bromodomain inhibitors as a method to disrupt the HPV 
life cycle. 
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4.2:  Introduction 
Papillomaviruses are small, double-stranded DNA viruses with an approximately 
8 kb episomal genome that can be divided into three regions:  the LCR, the early gene 
region, and the late gene region (Fig. 1.2, (80)).  The LCR contains the origin of 
replication and a transcriptional enhancer region containing multiple binding sites for the 
viral E2 protein and cellular transcription factors (41).  There are six early viral genes: 
E1, E2, E4, E5, E6, and E7.  These early genes are expressed from one or more early 
promoters as polycistronic mRNAs (80).  The prototypical papillomavirus, BPV1, has six 
early promoters that each encode a different polycistronic transcript while the high-risk 
HPVs, such as HPV types 16 and 18, only contain one early promoter (42, 91).  The 
polycistronic transcripts encoded from the early promoters utilize the same poly-
adenylation site and are processed by cellular splicing factors (92).   
Papillomavirus gene expression is strictly regulated by the differentiation status of 
the infected cell (81, 188).  During initial infection in basal epithelial cells, small amounts 
of E1 and E2 are expressed from the early promoter to support low-level maintenance 
replication of the viral genome.  The viral oncoproteins E6 and E7 promote proliferation 
of infected cells and establish a cellular environment conducive for the genome 
amplification stage of the PV life cycle (21).  Upon differentiation of the infected cells, 
the differentiation-dependent late promoter located within the E7 gene activates robust 
E1 and E2 expression to support viral genome amplification as well as expression of the 
L1 and L2 capsid proteins for assembly of new virions (81, 188).   
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E2 serves as the master regulatory protein of viral early gene transcription by 
binding to several sites upstream of the early promoter to tightly regulate viral gene 
expression (187).  This tight regulation ensures that just enough E6 and E7 are expressed 
to drive differentiated cells into S phase while avoiding the development of neoplasias 
and carcinomas which can be induced by E6/E7 over-expression (21).  E2 can both 
activate and repress transcription from the early promoter and this is thought to be 
partially regulated by E2 levels where low levels of E2 activates viral transcription while 
elevated E2 levels repress the viral early promoter (60, 192, 194).  E2 also recruits 
cellular transcription factors and chromatin modulatory proteins to the early promoter to 
mediate viral transcription activation and repression (96, 101, 109, 110, 174, 184).   
Brd4 is an important factor for cellular transcription as well as transcriptional 
regulation of a variety of different viruses including papillomaviruses, Epstein-Barr virus, 
and HIV (19, 86, 115, 223).  In cells, Brd4 interacts with the Cdk9 and Cyclin T1 
subunits of P-TEFb, displacing the negative regulators, HEXIM1 and 7SKsnRNA, from 
the P-TEFb complex to transform P-TEFb into its transcriptionally active form (19, 86, 
215).  Brd4 then recruits active P-TEFb to the transcription pre-initiation complex of 
many cellular genes where it stimulates transcription elongation by phosphorylating 
serine 2 in the C-terminal domain (CTD) of RNA polymerase II (86, 223).   
Interestingly, for papillomaviruses, Brd4 binding is important for E2’s dual 
transcription regulatory functions. (174, 184, 216).  In E2-dependent luciferase reporter 
assays where E2 expression stimulates luciferase gene transcription, Brd4 knock-down or 
abrogation of the E2-Brd4 interaction inhibits E2 transactivation of the luciferase reporter 
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(128, 174, 179).  Similarly, in luciferase reporter assays where E2 functions to repress 
luciferase gene expression, both Brd4 knock-down and disruption of the E2-Brd4 
interaction reduce E2’s ability to repress expression of the reporter gene (184, 216). 
Furthermore, in cervical cancer cells where the HPV genome is integrated into the 
cellular DNA and the E2 gene is disrupted, Brd4 activates viral oncogene transcription 
independently of E2 by recruiting P-TEFb to the HPV early promoter.  Upon 
reintroduction of E2 into these cells, E2 functions to repress viral oncogene expression by 
interacting with Brd4 and competitively inhibiting the Brd4-P-TEFb interaction (220).  
Wu et al. also showed that the transcription repression function of E2 and Brd4 is at least 
partially mediated by preventing the assembly of the pre-initiation complex near the viral 
promoter (216).  In contrast, the exact mechanism(s) whereby Brd4 contributes to viral 
transcription activation during papillomavirus infection is still unknown.   
In this study, we sought to uncover the mechanism underlying Brd4’s role(s) in 
E2-dependent transcription activation.  Using an E2-responsive reporter assay, we 
demonstrate that Brd4 recruitment of P-TEFb is important for E2-dependent 
transactivation.  We also found that P-TEFb is recruited to the native papillomavirus 
genome.  Furthermore, we provide evidence that Brd4 tethering of E2 to the cellular 
chromatin is necessary for the transactivation of the E2-responsive reporter.  Lastly, in 
cells carrying the papillomavirus genomes, we demonstrate that inhibiting Brd4’s 
association with cellular chromatin using the bromodomain inhibitor, JQ1(+), effectively 
reduces transcription of the viral early genes E1, E2, E6, and E7.  Together, these 
findings suggest that Brd4 interaction with E2 is not only necessary for recruiting P-
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TEFb to the papillomavirus early promoter, but might also be important for tethering E2 
and the viral genome complexes to particular regions of the cellular chromatin to support 
viral gene transcription. 
4.3:  Results 
4.3.1:  P-TEFb is Important for Papillomavirus E2-Mediated Transcription Activation 
Brd4 has previously been shown to assist E2 in transactivating viral genes but 
Brd4’s precise role in this process has remained elusive (128, 174).  Since Brd4 functions 
in cellular transcription activation mainly by recruiting P-TEFb to cellular gene 
promoters, we decided to investigate whether Brd4 activates papillomavirus transcription 
by recruiting P-TEFb to the viral promoters.  We first utilized an E2-responsive luciferase 
reporter assay to study this E2 transactivation function (100, 174).  The p2x2xE2BS-
luciferase reporter construct contains two pairs of E2 binding sites upstream of a minimal 
SV40 promoter and the luciferase gene (Fig. 4.1 A).  When either BPV1 E2TA or HPV16 
E2 is cotransfected with the reporter plasmid, it binds the E2 binding sites and activates 
the expression of luciferase (Fig. 4.1 B).  As previously reported, however, the E2 
mutants, BPV1 E2TR and HPV16 E2 R37A/I73A (16E2 RI), which do not bind Brd4, 
are unable to transactivate the luciferase reporter (Fig. 4.1 B) (128, 174).  We next 
determined if the defect in transcription activation observed in the Brd4 binding-deficient 
E2 mutants is due to their inability to recruit P-TEFb through Brd4 association.  To test 
this, we fused the Cdk9 subunit of P-TEFb to the E2 mutants, E2TR or 16E2 RI, and 
tested them in the luciferase reporter assay.  As shown in Fig. 4.1 B, Cdk9 fusion with 
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either E2TR or 16E2 RI mutant markedly restored the transactivation activities well 
above that seen for wild type E2TA and 16E2.  This enhanced transactivation activity 
was also observed when Cdk9 was fused to 16E2 WT or E2TA (data not shown).  The 
Cdk9 fusion to E2TR expressed at similar level as E2TR protein (Fig. 4.1 C) but the 
HPV16 E2 proteins express below the level detectable by Western blot, so it was not 
possible to compare their protein levels.  However, because both E2TR and 16E2 RI have 
been shown by us and others to be completely inactive in the E2 transactivation reaction 
(128, 224), this highly stimulated transactivation activity observed with the Cdk9-E2TR 
and Cdk9-16E2 RI constructs was not likely caused simply by a higher expression of 
these fusion proteins relative to E2TR or 16E2 RI. We further proved this by comparing 
the transactivation activity of low levels (1X) of Cdk9-E2TR or Cdk9-16E2 RI with 1X, 
2X, and 4X more of E2TR or 16E2 RI in the luciferase reporter assay.  As shown in Fig. 
4.1 D, while E2TR and 16E2 RI could not transactivate the luciferase reporter even when 
4 times more expression construct was transfected, very low levels of the Cdk9-E2 
mutant fusion proteins still robustly transactivated the luciferase reporter, confirming that 
the restored transactivation by the Cdk9-E2 mutant fusion proteins is not likely due to 
increased protein levels. It rather suggested a gain of function introduced by the Cdk9 
moiety of the fusion proteins.  These results demonstrate that P-TEFb is important for E2 
transactivation function, indicating that Brd4 likely functions to recruit P-TEFb to the E2-
responsive promoter to support viral transcription. 
We next tested whether fusing the E2 mutants to a kinase-dead Cdk9 D167N 
mutant (Cdk9m) abolished the transactivation activity of the fusion proteins (119).  The 
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D167N mutation did not affect the Cdk9-E2 fusion protein levels (Fig. 4.1 C).  These 
mutant Cdk9-E2 fusion constructs transactivated the luciferase reporter expression at a 
consistently lower level than the E2 mutants fused to wild type Cdk9, although their 
activity was still well above that seen for WT E2 proteins (Fig. 4.1 B).  This is likely 
because the Cdk9 D167N mutant retains some low-level kinase activity.  Alternatively, 
because this Cdk9 D167N mutant can still bind Brd4 and we have previously shown that 
Brd4 can form Brd4-Brd4 homodimers (206, 223), we suspect that Brd4 dimers bound to 
Cdk9 D167N-E2 can recruit endogenous P-TEFb to the luciferase reporter to partially 
activate transcription elongation of the luciferase gene.   
4.3.2:  P-TEFb is Recruited to the Papillomavirus Genome 
To confirm the role of P-TEFb in viral genome transcription, we tested if P-TEFb 
is recruited to the native papillomavirus genome.  For this set of experiments we used the 
H2 and W12 (clone 20863) cells that maintain either BPV1 or HPV16 episomal genomes, 
respectively (107, 191).  Both of these cell types stably maintain the viral episomes and 
support papillomavirus early promoter transcription (4, 5, 172, 226).  ChIP assays were 
performed with a Cdk9 antibody to examine the occupancy of P-TEFb on the 
papillomavirus genome.  As a positive control, an affinity purified Brd4 N-terminal 
antibody was also used in the ChIP analysis since Brd4 is known to associate with the 
papillomavirus genome through its interaction with E2 (224).  Primers recognizing either 
the BPV1 or HPV16 genome were used in ChIP qPCR to detect the binding of P-TEFb 
and Brd4 to the viral episome as we have described previously (226).  Both Cdk9 and 
Brd4 antibodies immunoprecipitated the BPV1 and HPV16 genomes at significantly 
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higher levels than the negative control ChIP using normal rabbit IgG (NRIgG) (Fig. 4.2 A 
and B). Importantly, no BPV1 or HPV16 signal was detected by qPCR from ChIP 
experiments using uninfected C127 cells, confirming that these primers specifically 
amplify a segment of the viral genome (data not shown).  These results demonstrate that 
P-TEFb is recruited to the papillomavirus episome likely through interaction with Brd4. 
4.3.3:  Brd4 CTD Disrupts Papillomavirus Transcription Activation by the Cdk9-E2 
Fusion Proteins 
E2 and P-TEFb both interact with the extreme C-terminus of Brd4 and expression 
of the Brd4 CTD effectively inhibits Brd4’s interaction with these two proteins (86, 220, 
223, 224).  In addition, Brd4 CTD abrogates E2 transactivation of the p2x2xE2BS-
luciferase reporter (174). Our findings suggest that this is likely because Brd4 CTD 
prevents the recruitment of Brd4 as well as P-TEFb to the E2-responsive promoter. We 
hypothesized that if Brd4’s only function in E2 transactivation is to recruit P-TEFb, then 
inhibiting Brd4’s interaction with E2 and P-TEFb using Brd4 CTD will likely have no 
effect on transactivation function of the E2 proteins that are already fused to P-TEFb. 
Surprisingly, when Cdk9-E2 fusion constructs were coexpressed with the Brd4 CTD 
expression construct, Brd4 CTD significantly inhibited the transactivation function of all 
Cdk9-E2 fusions (Fig. 4.3 A).  The weaker inhibition of Cdk9-E2TA by Brd4 CTD is 
likely because E2TA has a stronger binding affinity to Brd4 than HPV16 E2 so more 
Brd4 CTD is needed to efficiently break the E2TA-Brd4 interaction (128).  Indeed, we 
found that higher concentration of Brd4 CTD dramatically inhibited transactivation by 
Cdk9-E2TA (Fig. 4.3 B).  For an unknown reason, Brd4 CTD consistently increased β-
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galactosidase expression from the CMV promoter, which prevented us from normalizing 
the luciferase activity to β-galactosidase activity.  We instead examined E2 protein levels.  
Western blot analysis showed that Brd4 CTD expression does not decrease the levels of 
Cdk9-E2TA or Cdk9-E2TR.  Instead, as previously reported, Brd4 CTD even caused 
moderate stabilization of Cdk9-16E2 WT and Cdk9-16E2 RI proteins (Fig. 4.3 C) (108).  
Since the P-TEFb complex is already tethered to E2 by direct fusion, these results 
suggested that, other than recruiting P-TEFb, Brd4 likely has additional roles in E2-
mediated transactivation, which is tested in the experiments described below.  
Alternatively, it is possible that Brd4 CTD binds Cdk9 in the E2 fusions and induces a 
conformational change that abrogates P-TEFb function. 
4.3.4:  Releasing Brd4 From Chromatin by JQ1(+) Reduces E2-mediated Transcription 
Activation 
Previous studies published by Jang et al. showed that Brd4 directs E2 to 
transcriptionally active regions of cellular chromatin (85, 87).  We hypothesized that this 
recruitment of E2 by Brd4 to active regions of the nucleus would give the virus easy 
access to the cellular transcription machinery and thereby assist in E2-mediated 
transcription activation.  In this case, inhibiting Brd4 chromatin binding would likely 
impair E2-mediated transactivation.  To examine the importance of Brd4’s association 
with chromatin for E2 transactivation function, we abrogated Brd4’s interaction with 
acetylated histones on chromatin using a small molecule inhibitor, JQ1(+), as we have 
described previously (75, 208).  C33A cells stably expressing BPV1 E2TA were 
transfected with the p2x2xE2BS-Luciferase construct or an empty vector and then treated 
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with 500 nM of JQ1(+) or its inactive stereoisomer, JQ1(-), for 15 hours prior to the 
luciferase assay.  As shown in Fig. 4.4 A, E2TA transactivation of the luciferase reporter 
was drastically reduced in cells treated with JQ1(+) while cells transfected with empty 
vector had very low background luciferase activity.  A similar result was observed when 
C33A cells transfected with the HPV16 E2 and p2x2xE2BS-Luciferase constructs were 
treated for 15 hours with 500 nM of JQ1(+) or JQ1(-) prior to the luciferase assay (Fig. 
4.4 B).  Similar to Brd4 CTD expression, JQ1(+) consistently increased β-galactosidase 
levels precluding us from normalizing the luciferase reporter to this protein.  The E2 
protein levels, which were unaffected by JQ1(+) treatment, were used as transfection 
controls instead (Figs. 4.4 C and D).  Moreover, low levels of HPV16 E2 could still 
robustly activate luciferase expression in the presence of JQ1(-) whereas a high level of 
E2 protein was transcriptionally inactive with JQ1(+) treatment (Fig. 4.4 E and F).  This 
reduction in luciferase expression was also observed with as low as 100 nM JQ1(+) and 
as short as 8 hours of treatment (data not shown).  These results suggested that Brd4 
binding to chromatin is essential for E2 transactivation activity.  Together with the 
findings by Jang et al., we hypothesized that chromatin-bound Brd4 functions to direct 
E2 to transcriptionally active regions of the nucleus to facilitate E2 transcription 
activation (85, 87).   
To confirm that JQ1(+) abolishes E2’s association with cellular chromatin through 
interaction with Brd4, the strength of E2’s chromatin association in the presence of JQ1(-
) or JQ1(+) was examined as described by McPhillips et al. (129).  When HPV16 E2 and 
Brd4 are ectopically expressed in C33A cells, the E2-Brd4 complexes bound to cellular 
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chromatin appear as nuclear speckles in immunofluorescently-stained cells (Fig. 4.5 and 
(75)).  Treatment with JQ1(-) did not affect the localization of E2 and Brd4 in these 
speckles (Fig. 4.5, JQ1(-) unextracted).  However, after only 2 hours of JQ1(+) treatment, 
E2 and Brd4 no longer localized to small speckles but instead formed larger, punctate 
nuclear spheres or became diffuse in the nucleus (Fig. 4.5, JQ1(+) unextracted).  These 
large spheres formed by E2 and Brd4 in the presence of JQ1(+) has been described 
previously and were shown to be E2-Brd4 complexes that form off the cellular chromatin 
(see Chapter 2, (75)).  The strength of E2’s binding to cellular chromatin was next tested 
by pre-extracting proteins using solutions with increasing salt concentrations prior to cell 
fixation. In this experiment, the cells were incubated in buffer containing NP-40 (to 
permeablize the nucleus) and different salt concentrations (to extract proteins unbound or 
weakly bound to cellular chromatin).  All proteins besides those tightly bound to 
chromatin were washed away and then the cells were fixed for immunofluorescence 
analysis.  Upon JQ1(-) treatment, Flag-16E2 and Brd4 remained associated with cellular 
chromatin in nuclear speckles after pre-extraction with buffer containing up to 250 mM 
NaCl (Fig. 4.5).  Conversely, with JQ1(+) treatment and pre-extraction with 150 mM 
NaCl, only diffuse Flag-16E2 and Brd4 staining was detected in the nucleus but pre-
extraction with higher salt concentrations removed nearly all of the Flag-16E2 and Brd4 
signals (Fig. 4.5).  Similar results were observed with BPV1 E2TA (data not shown).  
This experiment demonstrates that Brd4 release from chromatin by JQ1(+) treatment 
weakens E2’s association with chromatin, confirming that Brd4 mediates E2 binding to 
cellular chromatin. 
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4.3.5:  JQ1(+) Treatment Reduces Papillomavirus Gene Expression 
In the next experiment, we examined whether JQ1(+)-induced dissociation of 
Brd4 from chromatin could also repress E2-mediated transactivation of gene transcription 
from the native papillomavirus genome.  For this study, H2 and W12 (clone 20863) cells 
were treated with JQ1(-) or JQ1(+) for 15 hours prior to mRNA isolation. Viral gene 
expression was measured with qRT-PCR using primers specific for either the BPV1 or 
HPV16 early genes: E1, E2, E6, and E7.  As shown in Fig. 4.6, JQ1(+) treatment caused 
efficient repression of all the viral early genes compared to JQ1(-) treatments (Fig. 4.6 A 
and B).  This reduction in viral transcripts was not due to any effect of JQ1(+) on 
papillomavirus episome levels (Fig. 4.6 C and D).  Notably, GAPDH mRNA levels were 
not significantly affected by the JQ1(+) treatment, indicating that JQ1(+) does not induce 
a global shutdown of cellular gene transcription.  It is also important to note that both H2 
and W12 cells looked healthy and grew normally after 15 hours of JQ1(+) treatment, 
suggesting that the reduced viral mRNA levels did not result from any impact of JQ1(+) 
on cell proliferation.  These results, together with the findings in Figs. 4.4 and 4.5, 
suggest that JQ1(+) releases E2 and Brd4 from cellular chromatin and this dissociation 
correlates with dramatically reduced transcription of the papillomavirus early genes.  
However, the papillomavirus genome also associates with cellular histones and assembles 
into minichromosomes so it is possible that the Brd4 bromodomains directly interact with 
viral minichromosomes and abrogating this interaction might also inhibit viral 
transcription (49, 167).   
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4.4:  Discussion 
Brd4 has long been known to function in papillomavirus transcription activation 
but its precise role in this process remained elusive.  Here, P-TEFb was found recruited to 
the papillomavirus genome along with Brd4 and was also shown to restore transactivation 
function to Brd4 binding-deficient E2 mutants, suggesting an important role of Brd4/P-
TEFb recruitment for papillomavirus transcription activation.  Furthermore, our work is 
the first to identify JQ1(+) as a potent inhibitor of papillomavirus gene expression, 
suggesting an important role of Brd4’s chromatin association for viral transcription 
regulation.  These findings support a model of Brd4 function in E2-dependent viral 
transcription activation (Fig. 4.7). 
E2 and Cdk9 both interact with the extreme C-terminal region of Brd4 (86, 220, 
223, 224).  This raises the question as to how Brd4 associates with E2 at the viral 
promoter while also recruiting P-TEFb. Our earlier report demonstrated that Brd4 
proteins can interact intermolecularly to form homodimers (206).  We therefore predict 
that Brd4 dimerizes at the papillomavirus transcription complex (Fig. 4.7).  It has been 
well established that low levels of E2 activate viral transcription whereas elevated E2 
levels repress the viral early promoter (60, 192, 194).  It is possible that, in the presence 
of low-level E2 expression, one Brd4 protein in the homodimers associates with E2 on 
the viral promoter while the other recruits P-TEFb.  These molecular interactions 
therefore allow E2 to recruit the Brd4/P-TEFb complexes to the viral promoter to 
stimulate viral transcription activation (Fig. 4.7).  On the other hand, high levels of E2 
protein can saturate all of the Brd4 C-terminal binding sites, thus replacing the Brd4-P-
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TEFb interaction and preventing the recruitment of P-TEFb to the viral promoter region 
for transcription activation. This could eventually lead to repression of viral transcription 
as has been observed when E2 is ectopically expressed in cells with integrated HPV 
genomes (220).  Future studies will test this hypothesis and determine whether Brd4 
dimerization is essential for PV transcription regulation.  
JQ1(+) treatment potently inhibited transactivation of the p2x2xE2BS-Luciferse 
reporter and the papillomavirus early promoters.  This transcription inhibitory effect by 
JQ1(+) is specific for papillomaviruses since GAPDH mRNA levels were not 
significantly affected by JQ1(+) and expression of beta-galactosidase from a constitutive 
CMV promoter was actually elevated with JQ1(+) treatment.  This observation also 
suggests that JQ1(+)-induced inhibition of E2 transcription activation is not a 
consequence of global gene expression shutdown.  In fact, it was recently found that 
JQ1(+) effectively reactivates HIV transcription in latently infected cells (13, 22). The 
JQ1(+)-induced inhibition of E2 transcription activation was also observed with only 8 
hours of treatment, suggesting that this inhibition effect is not likely due to an impact on 
the cell cycle.  Furthermore, we did not detect a significant change in papillomavirus 
genome levels in H2 and W12 cells after 15 hours of JQ1(+) treatment.  In a previous 
study we showed that JQ1(+) activates HPV16 genome replication in a transient 
transfection experiment, which would likely result in increased viral genome copies 
(Chapter 3, (208)).  However, with the drastically reduced viral transcript levels in 
combination with abrogated viral genome maintenance in dividing cells infected with 
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native viruses (Chapter 2, (75)), we predict that prolonged JQ1(+) treatment would 
eventually induce a pronounced loss of the papillomavirus episomes. 
Other than Brd4, JQ1(+) also affects the chromatin association of all BET family 
members as well as other bromodomain-containing proteins (51).  We therefore sought to 
specifically inhibit Brd4 chromatin binding to determine if the reduced papillomavirus 
transcription is exclusively from Brd4 inhibition.  We previously utilized ectopic 
expression of the Brd4 double-bromodomains (BDI/II) to dissociate Brd4 from chromatin 
and showed that Brd4 BDI/II does not affect Brd2 chromatin binding, indicating that this 
is a more specific method to abrogate Brd4 chromatin interactions (206).  Unfortunately, 
although Brd4 BDI/II efficiently inhibited the E2 transactivation activities, it also 
drastically destabilized the E2 protein, preventing us from fairly assessing the effect of 
BDI/II on E2-mediated transcription activation (data not shown).  However, because 
Brd4 is the only bromodomain-containing protein that carries the C-terminal domain for 
E2 binding, the observed JQ1(+) effects on E2 chromatin association and transcription 
activation are not likely resulted from the inhibition of other JQ1(+) targets besides Brd4.  
Our analysis of E2 and Brd4 chromatin association upon JQ1(+) treatment 
demonstrates that E2’s chromatin association matches that of Brd4.  Given that the other 
BET family members do not interact with E2, we believe this experiment suggests that 
Brd4 tethering of E2 to cellular chromatin might play an important role in E2 
transcription activation of viral genes.   Our observations are in line with the study 
published by Schweiger et al., which showed that Brd4 binding is required for E2 
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transcriptional activation (174). The authors found that inhibiting E2-Brd4 with Brd4 
CTD or knocking-down Brd4 with siRNA significantly reduced E2-dependent 
transcription activation, demonstrating a role for Brd4 in the transcriptional activation 
function of E2.  In studies from the McBride group, it was shown that Brd4 directs E2 to 
actively transcribed regions of cellular chromatin (85, 87).  We predict the virus might 
rely on Brd4 to take its genome to areas of the nucleus where it can efficiently co-opt the 
cellular transcriptional machinery.  However, this is not the only possible explanation to 
account for our findings so further studies are needed to confirm this hypothesis.  For 
example, Brd4 is involved in transcription activation of a number of cellular genes and 
JQ1(+) has been shown to inhibit transcription of some of these genes (34, 148, 207, 
234).  It is therefore possible that at least part of the reduction in papillomavirus 
transcription from JQ1(+) treatment is due to a loss of cellular transcription factors 
important for papillomavirus transcription.  Furthermore, Brd4 might contribute to other 
functions necessary for viral transcription.  For instance, the papillomavirus episomal 
genome assembles into viral minichromosomes with cellular histones and it is possible 
that Brd4 binds acetylated histones on the viral genome (49, 167).  This binding might 
serve to recruit chromatin modulating factors or other transcription factors to the viral 
promoters.  Additionally, we have observed that Brd4 can phosphorylate E2 in vitro (data 
not shown).  It will be interesting to determine if this Brd4 function can be detected in 
cells once a suitable antibody is generated and if this could be a regulatory switch by 
which Brd4 controls E2’s transcription functions. Uncovering the mechanisms underlying 
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E2 and Brd4 function in viral transcription regulation will provide a better understanding 
of how HPV gene expression is regulated throughout the viral life cycle. 
We previously showed that JQ1(+) has the potential to be a valuable tool to 
eliminate HPV infection since it can not only release E2-Brd4 complexes from mitotic 
chromosomes, which could disrupt viral episome maintenance, but also stimulate HPV16 
DNA replication, which could trigger an early and inopportune antiviral immune 
response (Chapter 2 and 3, (75, 208)).   In this study, we further discovered that JQ1(+) 
also abrogates papillomavirus gene expression.  Future studies will address the important 
question of whether the combined effects of JQ1(+) on the HPV life cycle result in 
clearance of HPV persistent infection.    
 
4.5: Figures 
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Figure 4.1  
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Figure 4.1.  P-TEFb is important for E2-mediated papillomavirus transcription 
activation. (A) Schematic diagram of the 2x2xE2BS-Luciferase reporter.  Two pairs of 
E2 binding sites (E2BS) are upstream of the minimal SV-40 promoter and firefly 
luciferase gene.   (B) C33A cells were cotransfected with p2x2xE2BS-Luciferse, CMV-
β-gal, and either an empty vector (Vector), a Cdk9 expression plasmid (Cdk9), or the 
indicated E2 expression plasmids.  Forty-eight hours post transfection, the cells were 
processed for luciferase and beta-galactosidase measurements. The luciferase values were 
normalized to beta-galactosidase expressed from a constitutive CMV promoter. Average 
and standard deviation were calculated from three experiments. (C) Nuclear proteins 
from cells transfected as in (B) were extracted and immunoblotted using anti-Xpress and 
anti-GAPDH antibodies.  (D) Cells were cotransfected as in (B) but with 1X of the Cdk9-
E2 fusion constructs or increasing amounts of E2TR/16E2 RI (1X, 2X, or 4X).  Empty 
vector was used to make the amount of DNA used for each transfection equal.  Forty-
eight hours post transfection, the cells were processed for luciferase activity and beta-
galactosidase activity measurements.  Average and standard deviation were calculated 
from three experiments.  
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Figure 4.2 
 
 
 
Figure 4.2.  P-TEFb is recruited to the papillomavirus genome. (A) H2 cells were 
subjected to ChIP assay using normal rabbit IgG (NRIgG), Brd4NA antibody, or anti-
Cdk9 antibody. ChIP samples were analyzed by qPCR using primers targeting the BPV1 
genome.  (B) W12 (clone 20863) cells were subjected to ChIP assay as in (A) and ChIP 
samples were analyzed by qPCR using primers targeting the HPV16 genome.  For both 
(A) and (B), the values represent the average and standard deviation of three independent 
experiments. 
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Figure 4.3 
 
 
 
Figure 4.3.  Brd4 CTD inhibits transcription activation by the Cdk9-E2 fusion 
proteins. (A) Along with the p2x2xE2BS-Luciferase construct, C33A cells were 
cotransfected with the indicated Cdk9-E2 fusion constructs and either an empty vector 
(Vector) or Brd4 CTD expression construct at a 1:6 ratio (Cdk9-E2:V/CTD). Forty-eight 
hours post transfection, the cells were processed for luciferase activity measurement.  (B) 
Cells were transfected as in (A) except a 1:8 ratio of Cdk9-E2TA:V/CTD was used.   
Forty-eight hours post transfection, the cells were processed for luciferase activity 
measurement.  In (A) and (B), average and standard deviation were calculated from three 
experiments. (C) Cells were transfected as in (A) and nuclear lysates were 
immunoblotted with anti-Xpress and anti-GAPDH antibodies.   
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Figure 4.4 
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Figure 4.4.  JQ1(+) inhibits E2 transcription activation. (A) C33A cells stably 
expressing Flag-HA-tagged BPV1 E2TA were transfected with empty vector (Vector) or 
the p2x2xE2BS-Luciferase construct.  At thirty-three hours post transfection, the cells 
were treated with 500 nM JQ1(-) or JQ1(+) until collection at forty-eight hours post 
transfection.  The cells were processed for luciferase activity measurement.  (B) C33A 
cells were cotransfected with the p2x2xE2BS-Luciferase construct and an empty vector 
(Vector) or the Flag-16E2 construct.  As in (A), the cells were treated with 500 nM JQ1(-
) or JQ1(+) for 15 hours then collected at forty-eight hours post transfected for luciferase 
activity measurement.  Average and standard deviation were calculated from three 
experiments for (A) and (B).  (C) Cells stably expressing Flag-HA-tagged BPV1 E2TA 
were transfected and treated with JQ1 as in (A).  Nuclear proteins were harvested and 
immunoprecipitated with anti-Flag (M2) beads.  The precipitates were immunoblotted 
with anti-HA-HRP antibody.  GAPDH levels were analyzed from the input with anti-
GAPDH antibody.  (D) C33A cells were transfected and treated with JQ1 as in (B).  
Protein extracts were immunoblotted with anti-HPV16 E2 and anti-actin antibodies.  (E) 
C33A cells were cotransfected as in (B) except with increasing amounts of 16E2 (1/3X, 
1/2X, 1X).  Empty vector was used to make the amount of DNA used for each 
transfection equal.  The cells were treated with JQ1 and collected for luciferase activity 
measurement as in (B).  The average and standard deviation were calculated from three 
experiments.  (F) Cells were transfected and treated with JQ1 as in (E).  Protein extracts 
were immunoblotted with anti-HPV16 E2 and anti-actin antibodies. 
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Figure 4.5 
 
Figure 4.5. JQ1(+) releases E2 from chromatin.  C33A cells were cotransfected with 
Flag-16E2 and Brd4 expression constructs at a 1:1 ratio.  Two hours prior to collection, 
cells were treated with 500 nM JQ1(-) or JQ1(+).  Forty-eight hours post transfection, 
coverslips were collected and either fixed immediately (unextracted) or pre-extracted in 
buffer containing the indicated concentration of NaCl prior to fixation.  The coverslips 
were then stained with anti-Flag (green) and anti-Brd4CA (red) antibodies and 
counterstained with DAPI.  This experiment was repeated a total of three times and the 
most representative images are presented.  Bar, 5 μm. 
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Figure 4.6 
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Figure 4.6. JQ1(+) treatment inhibits papillomavirus early gene expression. (A) H2 
cells were treated with 1 μM JQ1(-) or JQ1(+) for 15 hours.  RNA from these cells was 
reverse transcribed and the levels of the indicated BPV1 early gene mRNAs were 
measured by qRT-PCR.  The mRNA level for each viral gene was normalized to GAPDH 
mRNA level.  The JQ1(+)-treated sample values are presented relative to the JQ1(-) 
sample values.  (B) W12 (clone 20863) cells were treated with 100 nM JQ1(-) or JQ1(+) 
for 15 hours.  As in (A), RNA was collected and reverse transcribed and the cDNA was 
used in qRT-PCR analyses to measure HPV16 early gene mRNAs.  The mRNA level for 
each viral gene was normalized to GAPDH mRNA level.  The JQ1(+)-treated sample 
values are presented relative to the JQ1(-) sample values.  (C) H2 cells were treated with 
1μM JQ1(-) or JQ1(+) for 15 hours. Whole genomic DNA was extracted and the BPV1 
episome level in each sample was measured using qPCR.  The BPV1 episome level was 
normalized to the GAPDH DNA level in the samples.  (D) W12 (clone 20863) cells were 
treated with 100 nM JQ1(-) or JQ1(+) for 15 hours and whole genomic DNA was 
extracted.  The HPV16 episome level in each sample was measured using qPCR.  The 
HPV16 episome level was normalized to the GAPDH DNA level in the samples.  For all 
these experiments, the average and standard deviation were calculated from three 
independent experiments.   
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Figure 4.7 
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Figure 4.7. A model of Brd4 functions in E2-mediated viral transcription activation. 
Papillomavirus E2 protein binds to the E2 binding sites (E2BS) upstream of the early 
promoter as a dimer.  E2 interacts with Brd4 at the C-terminus while the N-terminal Brd4 
bromodomains direct E2 and the viral genome to transcriptionally active regions of the 
cellular genome.  Brd4 can form homodimers and also recruit P-TEFb to the viral 
promoter to phosphorylate the RNA pol II CTD to activate transcription elongation.  
However, JQ1(+) blocks Brd4 association with cellular chromatin, impeding the 
recruitment of the viral genomes to transcriptionally active areas of the cellular genome 
and thereby inhibiting E2-mediated transcription activation of the papillomavirus 
promoters.  The Brd4-CTD can abrogate the E2-Brd4 interaction as well as the Brd4-
Cdk9 interaction, thus blocking P-TEFb recruitment to the viral promoter and preventing 
the activation of transcription elongation by P-TEFb. 
 
 
 
 
 
 
 
118 
	  
Table 4.1. The qPCR primer sequences used in Figures 4.2 and 4.6. 
Primer Name Primer Sequence 
BPV1 Genome Forward 
 
5’ GAAGAGGATGGAGACAGCATGC 3’ 
 
BPV1 Genome Reverse 
 
5’ TCTGTGCGCATGTACAAATTGC 3’ 
 
HPV16 Genome Forward 
 
5’ CAATGCGACACAAACGTTCTGC 3’ 
 
HPV16 Genome Reverse 
 
5’ CTATAGAAGGATCGGAAGGG 3’ 
 
BPV1 E6 Forward 
 
5’ TCCATTCTCAGGGTTGGATTG 3’ 
 
BPV1 E6 Reverse 
 
5’ CACAGTAGCAGCATCTTATGC 3’ 
 
BPV1 E7 Forward 
 
5’ CGTTGCTGATTTTAAGTCCATGTG 3’ 
 
BPV1 E7 Reverse 
 
5’ GTCTTCACAGCAAAAGTCAGCT 3’ 
 
BPV1 E1 Forward 
 
5’ CTGACTGAGGCAGAATGTGAAAG 3’ 
 
BPV1 E1 Reverse 
 
5’ TGGAGTTTCAGATGCTTCGG 3’ 
 
BPV1 E2 Forward 
 
5’ GCTGTTAGAACTGAGAACACACTG 3’ 
 
BPV1 E2 Reverse 
 
5’ GCCTTTCTTAAAGCACCGTTTAGG 3’ 
 
Mouse GAPDH Forward 
 
5’ CCAGCCTCGTCCCGTAGA 3’ 
 
Mouse GAPDH Reverse 
 
5’ CGCCCAATACGGCCAAA 3’ 
 
HPV16 E6 Forward 
 
5’ TACCACAGTTATGCACAGAGC 3’ 
 
HPV16 E6 Reverse 
 
5’ GCTTTTCTTCAGGACACAGTG 3’ 
 
HPV16 E7 Forward 
 
5’ GCATGGAGATACACCTACATTGC 3’ 
 
HPV16 E7 Reverse 
 
5’ CGAATGTCTACGTGTGTGCTTTG 3’ 
 
HPV16 E1 Forward 
 
5’ GAAGAGGGTACGGGATGTAATG 3’ 
 
HPV16 E1 Reverse 
 
5’ CATGTGCTGTCTCTGTTTCTGC 3’ 
 
HPV16 E2 Forward 
 
5’ CAGACCTACGTGACCATATAGACT 3’ 
 
HPV16 E2 Reverse 
 
5’ CTGCACTTCCACTGTATATCCATG 3’ 
 
Human GAPDH Forward 
 
5’ GTGAAGGTCGGAGTCAACGGA 3’ 
 
Human GAPDH Reverse 
 
5’ CCATGGGTGGAATCATATTGGAAC 3’ 
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CHAPTER 5:  Conclusions and Future Directions 
5.1:  Brd4 Inhibition as a Method to Clear Viral Infection 
5.1.1: Brd4 Inhibition to Disrupt the HPV Life Cycle  
 In this thesis, I have studied the interaction between HPV16 E2 and Brd4 as well 
as the importance of this interaction for different viral functions.  More importantly, I 
have identified the BET inhibitor, JQ1, as a promising tool to abrogate critical events of 
the HPV life cycle.  My studies demonstrated that Brd4 association with chromatin is 
necessary for HPV16 E2-Brd4 complexes to bind mitotic chromosomes (Chapter 2), 
suggesting that Brd4 is important for HPV16 E2-mediated episome maintenance during 
the early stage of HPV infection.  This result also suggests that JQ1 treatment could be an 
effective method to abrogate this E2 function, which could result in loss of viral genomes 
with each cell division. 
 I also found that Brd4 is essential for HPV genome replication and that releasing 
Brd4 from chromatin after JQ1 treatment actually enhances viral replication.  From the 
perspective of trying to treat a persistent HPV infection, elevated viral replication might 
initially seem undesirable.  However, during the persistent phase of the HPV life cycle, 
the virus maintains its genomes at a very low copy number to avoid activation of the host 
immune response.  Therefore, premature induction of viral genome amplification during 
persistent infection might trigger an immune response to clear the viral infection.  This 
hypothesis can be tested using a mouse model of HPV infection since mice have been 
shown to tolerate JQ1 with minimal adverse effects (25, 51). 
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 Lastly, we have discovered that JQ1 treatment dramatically reduces 
papillomavirus transcription suggesting that Brd4-mediated HPV association with 
cellular chromatin is important for papillomavirus gene transcription.   It is possible that 
Brd4 functions to direct E2 and the viral genomes to active regions of the nucleus so that 
the virus can easily access the cellular transcription machinery (85, 87).  Without this 
targeting effect, the viral transcription is very inefficient.   
 The next obvious question from these findings is what effect Brd4 bromodomain 
inhibition would have during an actual HPV infection when episome maintenance, viral 
replication, and viral transcription are all occurring at once.  I predict that the combined 
loss of viral genome maintenance and greatly reduced HPV gene transcription would be 
enough to disrupt the viral life cycle during an early HPV infection.  This obviously 
needs to be tested so future work will analyze cells that maintain a persistent HPV 
infection and determine if prolonged treatment with a non-toxic dose of JQ1 clears these 
cells of HPV infection.  Additionally, we can examine the effect of JQ1 on organotypic 
raft cultures of HPV31 infected cells (106).  Other have demonstrated that HPV31 
positive cells grown in organotypic raft cultures can produce and release virions from the 
upper cell layer (131).  It would therefore be interesting to determine if JQ1 treatment of 
these cultures disrupts the viral life cycle so that virions are no longer generated from the 
culture.   
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5.1.2:  Brd4 Inhibition as a Tool to Clear Other Viral Infections and Treat Virus-Related 
Diseases 
 As discussed in Section 1.4.4, a number of other viruses besides papillomaviruses 
utilize Brd4 for important viral functions.  It is therefore possible that inhibition of Brd4 
could be an effective method to disrupt the life cycles of these viruses as well.  
Interestingly, it was found that Brd4 is important for P-TEFb recruitment to the EBV C 
promoter for activation of EBNA gene transcription elongation (152).  Similar to our 
findings with papillomaviruses, this group demonstrated that Brd4 inhibition by JQ1 
significantly reduces transcription from the C promoter (152).  It will be interesting to 
determine if this repression of the EBNA latency genes has an impact on EBV latent 
infection.  
 During HIV infection, Brd4 competes with the HIV TAT protein for P-TEFb 
binding and thereby inhibits P-TEFb recruitment to the integrated viral genome and 
represses HIV gene transcription (19).  In addition, Brd2 acts as an important enforcer of 
HIV latency (22).  Since Brd4 and Brd2 both function to inhibit HIV lytic infection, it 
was not surprising that the BET inhibitors were found to relieve this repression of HIV 
transcription and effectively reactivate latent HIV (11, 22).  This finding identified JQ1 
and other BET inhibitors as promising drugs to reactivate latent pools of HIV so the 
infection can be treated and hopefully eliminated completely.   
 Besides viral infections, the BET inhibitors have shown great promise as a drug 
therapy for several types of cancers (see Section 1.3.5).  Recently, it was found that a 
type of non-Hodgkin’s lymphoma associated with KSHV infection is sensitive to BET 
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inhibition by JQ1 (197).  This group demonstrated that treatment of these cells with JQ1 
down-regulates Myc levels and causes cellular senescence, cell cycle arrest, and 
apoptosis.  This finding indicates that the BET inhibitors can also be useful tools to treat 
additional virus-associated diseases. 
5.2:  The Dynamic E2-Brd4 Interaction During the Viral Life Cycle 
5.2.1:  The Interaction Between E2 and Brd4 
 Using the BiFC technique, our studies demonstrated that HPV16 E2 interacts with 
Brd4 during all stages of mitosis, suggesting that this interaction is important for 
tethering E2 and viral episomes to mitotic chromosomes to ensure that the viral genomes 
are maintained between cell divisions.  Besides this important discovery, this study also 
demonstrated the usefulness of BiFC for analyzing protein-protein interactions in live or 
fixed cells throughout the cell cycle.   In the future, BiFC can be used to examine the 
interaction between other papillomavirus E2s and Brd4 at different cell cycle stages and 
throughout the HPV life cycle in order to better understand how this interaction is 
regulated and when during infection this interaction is most important. 
5.2.2:  E2 Transition Between E1 and Brd4 Binding 
 E1 and Brd4 interact with E2 on opposite faces of the E2 transactivation domain 
and therefore can potentially bind E2 simultaneously (1, 2).  However, we have observed 
that increasing E1 levels competitively inhibits Brd4’s interaction with E2 (Fig. 5.1).  It is 
therefore possible that E2’s transition between its roles in episome tethering, viral 
genome replication, and viral transcription is regulated by the relative abundance of E2, 
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E1, and Brd4 in cells.  E1 and E2 are expressed at a similar level in undifferentiated cells 
but upon cellular differentiation, expression of both proteins greatly increases with E1 
protein reaching a higher level than E2 (150).  Furthermore, in human skin, we found that 
Brd4 levels also increase upon cellular differentiation (data not shown).  Because the 
relative protein levels of E2, E1, and Brd4 change during the HPV life cycle, it will be 
interesting to test if these changes regulate the various E2 functions in the viral life cycle.   
 
Figure 5.1.  E1 inhibits Brd4’s association with E2 in a dose-dependent manner.  C33A 
cells were cotransfected with Flag-16E2 and differing amounts of HA-16E1 or empty 
vector (V) as indicated.  The empty vector was used as a negative control to make the 
final DNA concentration equal for all the transfections.  Forty-eight hours post 
transfection, nuclear extracts were immunoprecipitated with anti-Flag (M2) antibody.  
Both input samples and precipitates were immunoblotted with specific antibodies as 
indicated. 
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One report suggested that E2 phosphorylation status might regulate its binding to 
E1 (203).  This group showed that BPV1 E2 mutated at four serines in its hinge domain 
abolishes phosphorylation at these sites and increases E2 binding to E1 while reducing 
E2 association with mitotic chromatin.  Interestingly, we have found that Brd4 purified 
from insect cells can phosphorylate E2 in vitro (data not shown).  Future studies will 
determine if Brd4 actually phosphorylates E2 in vivo and assess whether E2 
phosphorylation affects E2’s binding to mitotic chromosomes and E1.  If these studies are 
successful, we can further examine E2 phosphorylation status throughout the HPV life 
cycle to gain a better understanding of how E2 function is regulated. 
5.3:  Brd4’s Roles During HPV Replication  
5.3.1:  Brd4’s Role During HPV Genome Replication  
	   Our study demonstrated that Brd4 association with E2 is essential for the 
formation of viral replication factories and for efficient replication of the HPV genomes 
(Chapter 3).  However, Brd4’s exact function during viral replication is still unclear.  
Similar to our hypothesis for Brd4’s role in viral transcription activation, we speculate 
that Brd4 might direct the viral replication complex to particular regions of the nucleus 
where the virus can access cellular replication proteins and DNA damage response 
factors.  This is supported by recent findings that Brd4 tethers the HPV replication 
complex to cellular chromatin near common fragile sites, which are especially prone to 
DNA damage (87).  It is also possible that Brd4 functions to directly recruit cellular or 
DNA damage response factors to the HPV replication foci.  Brd4 is known to interact 
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with RFC1 as well as the RFC homolog, ATAD5, which are both found in HPV 
replication foci (data not shown and (83, 121, 163, 208)).  Future efforts will focus on 
better understanding Brd4’s role(s) in HPV replication and, more specifically, 
determining if Brd4 functions to recruit cellular replication factors to HPV replication 
centers. 
 A recent study from the McBride group showed that Brd4 and cellular chromatin 
colocalize with early HPV replication foci but are eventually displaced from the viral foci 
as these foci mature into full-blown viral genome amplification factories (169).  This 
group speculated that displacement of Brd4 and cellular chromatin from viral replication 
foci might be necessary for HPV genome amplification to proceed (169).  In this model, 
Brd4 would function early during replication to direct the replication foci to specific 
nuclear domains in order to facilitate virus access to cellular replication and DDR factors.  
However, once these replication foci were established, Brd4 and the cellular chromatin 
would be displaced from viral foci to allow viral genome amplification to proceed. 
Intriguingly, in our study, we found that releasing Brd4 from cellular chromatin by JQ1 
stimulates HPV genome replication (Chapter 3).  It is possible that for replication foci 
established before JQ1 treatment, the release of Brd4 from cellular chromatin after JQ1 
treatment promotes the displacement of Brd4 and cellular chromatin from the viral 
replication foci and stimulates full-blown HPV genome amplification.   Future studies 
should further investigate Brd4 displacement from replication foci and determine whether 
this displacement is essential for viral genome replication.  Furthermore, it will be 
important to determine if viral replication factories need to eventually dissociate from 
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cellular chromatin to amplify the viral genomes and if JQ1 treatment promotes this 
detachment from cellular chromatin by releasing Brd4.    
5.4:  Brd4’s Roles in HPV Transcription Regulation 
5.4.1:  Brd4’s Role in Papillomavirus Transcription Activation 
	   Part of my thesis work focused on better understanding the role of Brd4 in 
papillomavirus transcription activation (Chapter 4).  I showed that Brd4 recruitment of P-
TEFb to the viral promoter is important for E2 transactivation function (Chapter 4).  
However, one question that remains is how Brd4 itself is recruited to the viral promoter.  
E2 recruitment is the simplest explanation but we have shown previously that E2 and P-
TEFb bind the same region on Brd4 and interfere with each other’s association with Brd4 
(220).  Therefore, the mechanism by which Brd4 and P-TEFb are recruited to the HPV 
transcription start site must be more complex.  We have previously shown that Brd4 can 
form homodimers so it is possible that one Brd4 molecule binds E2 at the viral promoter 
while the other Brd4 molecule in the homodimer associates with P-TEFb (see Fig. 4.7) 
(206).  To test this idea, we can mutate the dimerization domain within the Brd4 
bromodomains to abolish Brd4 dimerization and determine if Brd4 can still recruit P-
TEFb to the HPV promoters.  Alternatively, it is also possible that some Brd4 molecules 
interact independently of E2 with acetylated histones associated with the viral chromatin 
and thereby recruit P-TEFb to the papillomavirus promoter (49, 138, 167).  In this model, 
some Brd4 molecules would interact with E2 to enhance E2 stability and E2’s association 
with the promoter (108) while other Brd4 molecules would interact with viral chromatin 
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near the papillomavirus transcription start site independent of E2 in order to recruit P-
TEFb.   E2-independent localization of Brd4 to the HPV promoters can be assessed by 
determining if a Brd4-specific antibody can ChIP HPV genomes mutated to abolish E2 
expression.  In addition, we can assess whether JQ1(+) treatment affects Brd4’s ability to 
immunoprecipitate the papillomavirus episomes from infected cells.   
5.4.2: Brd4’s Role in Papillomavirus Transcription Repression 
Brd4 has also been shown to be important for E2’s transcription repression 
function (184, 216).  One study demonstrated that E2 and Brd4 act to repress 
papillomavirus transcription by preventing the assembly of the pre-initiation complex 
near the viral promoter (216).  However, it is also possible that Brd4 represses viral 
transcription by other mechanisms such as recruiting chromatin-remodeling factors or 
other transcription repression factors to the viral genome (184).  In future studies, we will 
focus on uncovering Brd4’s role(s) in papillomavirus transcription repression.  In 
addition, it will be interesting and important to determine how E2 and Brd4 transition 
between their transcription activation and repression functions during the viral life cycle. 
 
Concluding Remarks 
 This work studied a key virus-host interaction during the papillomavirus life 
cycle.  It demonstrates the remarkable ability of viruses to co-opt a single cellular factor 
to mediate multiple viral processes.  It also shows that specifically targeting this essential 
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virus-host complex can be an effective strategy to disrupt important stages of the viral life 
cycle.   
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CHAPTER 6: Materials and Methods 
 
Cell culture  
Cells of the human papillomavirus-negative cervical cancer cell line, C33A, were 
purchased from ATCC and maintained as monolayers in high glucose Dulbecco’s 
modified Eagle’s medium (DMEM, GIBCO) containing 10% fetal bovine serum (FBS, 
Hyclone) and 1% penicillin-streptomycin (Invitrogen).  The mouse fibroblast cell line 
maintaining BPV1 episomes, H2, were maintained as monolayers in DMEM containing 
10% FBS and 1% penicillin-streptomycin.  Generation of the C33A cells stably 
expressing Flag-HA-tagged E2TA was described previously (224).  The HPV16-positive 
cervical cancer epithelial cells, W12 (clone 20863), were provided by Dr. Paul Lambert 
and were maintained at subconfluence on mitomycin-c treated 3T3M feeder cells in F 
medium composed of 1 part DMEM and 3 parts F-12 medium (GIBCO) supplemented 
with 5% FBS, cholera toxin (8.4 ng/ml, Sigma), adenine (24 μg/ml, Sigma), epidermal 
growth factor (10 ng/ml, R&D), hydrocortisone (0.4 μg/ml, Millipore), and insulin (5 
μg/ml, Sigma) (53).  The Spodoptera frugiperda (Sf9) cell line was maintained as a 
monolayer in Sf-900 III Serum free medium (SFM, GIBCO).   
 
Transient transfections 
For immunofluorescence staining, immunofluorescence-fluorescence in situ 
hybridization (immuno-FISH) analysis, Southern blotting, and Western blotting, cells 
were transfected with FuGENE 6 (Promega) or Lipofectamine 2000 (Invitrogen) 
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transfection reagents following the manufacturers’ instructions.  For the in vitro 
replication assay, immunoprecipitation (IP) experiments, luciferase reporter assays, and 
Western blot analysis, cells were transfected using the calcium phosphate method. For 
calcium phosphate transfection, 25 µg DNA was mixed with 163 µl 2 M CaCl2 in a 1.3 
ml final volume. The DNA/CaCl2 mixture was slowly dropped into 1.3 ml 2×HBS (55 
mM HEPES, 0.4 M NaCl and 1.5 mM Na2HPO4, pH 7.0) while vortexing. The DNA 
mixture was then overlayed onto the cells with culture medium.  Small interfering RNA 
(siRNA) transfection was performed using the calcium phosphate method described 
above or DharmaFECT II siRNA transfection reagent (Thermo Scientific Dharmacon) 
following the manufacturer’s instructions.  For bromodeoxyuridine (BrdU) labeling, cells 
were transfected with FuGENE HD (Promega) following the manufacturer’s instructions.  
At 42 hours post transfection, the cells were treated with 10 μM BrdU for 20 minutes, 
washed 2 times with medium, and cultured an additional hour before being fixed with 
acetone. 
 
Reagents  
The compound, 4',6-diamidino-2-phenylindole (DAPI), was dissolved in water as 
a 500X stock (Invitrogen).  siGENOME siRNAs targeting human BRD4 and control non-
targeting siRNA 1 were purchased from Thermo Scientific Dharmacon.  The Brd4 
bromodomain-specific inhibitor, JQ1(+), and its isomer compound, JQ1(-), were from Dr. 
James Bradner and were dissolved in dimethyl sulfoxide (DMSO) as 1000X stocks.  
BrdU (Sigma) was dissolved in DMSO to 10 mM.   
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Recombinant plasmid construction  
The pUC19-HPV16 plasmid containing HPV16 genome inserted into the BamHI 
site of pUC19 and the pEFHPV-16W12E plasmid were gifts from Dr. Paul F. Lambert. 
HA-16E1 was provided by Dr. Mart Ustav. CMV4-Flag16E2 has been described 
previously (224).  The cDNA for full-length human Brd4 was PCR amplified and 
subcloned into the BamHI and NotI sites of pcDNA4/HisMax C vector (pcDNA4C, 
Invitrogen) to generate pcDNA4C-hBrd4, in which human Brd4 was fused with an 
Xpress tag on the N-terminus. The Brd4 gene was also inserted into the BamHI/XhoI 
sites of pGEX-6P-1 (GE Healthcare) to obtain pGEX-6P-1-hBrd4 producing a GST-
tagged hBrd4 protein.  pOZN-HPV16 E2 encodes a codon optimized E2 gene fused to 
HA and Flag tags on its N-terminus and was generated by subcloning the HPV16 E2 
coding sequence into the pOZN vector using XhoI and NotI sites.  HPV16 E2 was PCR 
amplified and inserted into BamHI/XhoI sites of pEGFPC1 (Clontech) to obtain GFP-
16E2.  HPV16 E2 mutant plasmids, GFP-16E2 E39A, GFP-16E2 R37A/I73A, GFP-16E2 
R304K, CMV4-Flag16E2 E39A, CMV4-Flag16E2 R37A/I73A, CMV4-Flag16E2 R37A, 
CMV4-Flag16E2 I73A, and pOZN-VC-16E2 R37A/I73A were constructed using 
QuikChange site-Directed Mutagenesis Kit (Stratagene) following the manufacturer’s 
protocol. To obtain pHPVOri, the HPV16 replication Ori (7855 nt - 96 nt in HPV16 
genome) was PCR amplified using primers 5’GCGGATCCCAAACCGTTTTGGGTT3’ 
and 5’GCGGATCCCTCTTTTGGTGCATAAAATG3’, and inserted into the BamHI site 
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of pcDNA4/HisMax C vector.  The HA-16E1 open reading frame including its upstream 
promoter and downstream polyadenylation signals was digested with EcoRI/XhoI 
restriction enzymes and inserted into the EcoRI/XhoI sites of pHPVOri and 
pcDNA4/HisMax C to obtain pHPVOri/E1 and HA-16E1, respectively.  The HPV16 
genome was isolated from pUC19-HPV16 by BamHI digestion and re-ligation was 
performed under a very diluted condition (3-4 µg/ml).  Un-ligated DNA was removed 
using Plasmid-Safety ATP-dependent DNase (Epicentre) following the manufacturer’s 
protocol.  To construct the plasmid encoding Xpress-tagged Brd4-CTD (pcDNA4C-NLS-
Brd4-CTD), the SV40 nuclear localization signal (NLS) was inserted in frame in front of 
the Brd4-CTD (Brd4aa 1047-1362) coding region by PCR and the product was subcloned 
into pcDNA4C using BamHI and NotI sites.  The Venus N (Venus aa 1-155) and Venus 
C (Venus aa 156-238) coding sequences were amplified from pCS2-Venus provided by 
Dr. Atsushi Miyawaki.   To construct Brd4 or E2 fusions with VN or VC, a short linker 
sequence (GGSGG) was introduced in the C-terminal end of VN/VC fragments by PCR, 
and the amplified DNA fragments were cloned into the pOZN vector at the XhoI site.  
Brd4, E2TA, E2TR or 16E2 DNA fragments excised from their pOZN constructs using 
XhoI and NotI digestion were ligated into pOZN-VN-short linker and pOZN-VC-short 
linker to generate in-frame fusions of these molecules with either Venus N or Venus C. 
The pcDNA4C-NLS-LacI plasmid was generated by cloning an NLS into the pcDNA4C 
vector using a BamHI site and the PCR-amplified LacI cDNA fragment into the 
pcDNA4C vector using BamHI and EcoRI sites. For the pcDNA4C-Cdk9 construct, 
Cdk9 cDNA was PCR amplified and subcloned into the EcoRI and NotI sites of 
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pcDNA4C.  The E2 expression constructs pcDNA4C-E2TA, pcDNA4C-E2TR, 
pcDNA4C-16E2, and pcDNA4C-16E2 R37A/I73A were generated by PCR amplifying 
the indicated E2 gene and subcloning into the EcoRI and NotI sites of pcDNA4C.  For 
pcDNA4C-Cdk9-E2TA, pcDNA4C-Cdk9-E2TR, pcDNA4C-Cdk9-16E2, and 
pcDNA4C-16E2 R37A/I73A, the Cdk9 gene was fused to the indicated E2 gene using 
PCR.  This fusion product was then subcloned into the EcoRI and NotI sites of 
pcDNA4C.  The constructs containing Cdk9 D167N were generated by mutating the 
indicated site using the QuikChange site-directed mutagenesis kit (Stratagene).  pCMV-
LacZ (β-galactosidase) was purchased from Clontech.  The 2x2xE2BS-Luciferase 
reporter was described previously (100, 187).  All plasmid constructs were verified by 
DNA sequencing.   
 
IF staining and immuno-FISH 
Cells were cultured on coverslips and fixed with 3% paraformaldehyde (PFA) in 
phosphate-buffered saline (PBS) for 20 minutes.  The coverslips were then incubated in 
blocking/permeabilization buffer (3% bovine serum albumin and 0.5% Triton X-100 in 
PBS) and then incubated with primary antibodies for 1 hour at room temperature.  After 
incubation, cells were washed 3 times using blocking/permeabilization buffer and 
incubated with fluorescently labeled secondary antibodies for 1 hour.  In some cases, 
cells were counterstained with 4’, 6’-diamidino-2-phenylindole (DAPI). 
For experiments with pre-extraction prior to cell fixation (Fig. 4.5), cells grown 
on coverslips were pre-extracted on ice for 10 minutes in CSK buffer (10 mM PIPES (pH 
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6.8), 30 mM sucrose, 3 mM MgCl2, 1 mM EGTA, 0.5% Triton X-100, from 150 to 300 
mM NaCl, and supplemented with protease inhibitors) before being fixed with 4% PFA 
in PBS for 20 minutes.  The coverslips were then incubated in blocking/permeabilization 
buffer and then incubated with primary antibodies for 1 hour at room temperature.  After 
incubation, cells were washed 3 times using blocking/permeabilization buffer and 
incubated with secondary antibodies for 1 hour.  The cells were counterstained with 
DAPI. 
For immuno-FISH staining, cells were fixed with 1% PFA for 10 minutes at room 
temperature and washed with cold PBS twice on ice.  Proteins were stained following the 
IF protocol described above and RNA was digested with 25 μg/ml RNase A for 1 hour at 
37°C.  Cells were then fixed with 4% PFA for 10 minutes at room temperature, washed 
with cold PBS twice, washed with 2X SSC (300 mM NaCl, 30 mM trisodium citrate, pH 
7.0) twice, and once each with 70%, 80%, and 100% ethanol.  Probes were labeled with 
biotin-dUTP (AppliChem) using a nick translation assay and incubated with cells for 5 
minutes at 95°C.  Cells were then incubated in a moist chamber at 37°C overnight.  The 
in situ hybridization signal was developed using the Trypticase soy agar (TSA)-biotin 
system (PerkinElmer) following the manufacturer’s instructions. 
Primary antibodies used for IF and immuno-FISH include: anti-Xpress 
(Invitrogen), anti-HA (Santa Cruz), anti-Flag M2 (Sigma), anti-RFC1 (H-300) (Santa 
Cruz), anti-RPA70 (Cell Signaling), anti-BrdU (Invitrogen), anti-Brd4C (recognizing 
Brd4 aa1313-1362), and anti-DNA polymerase δ (Santa Cruz).  Secondary antibodies 
used include: Alexa Fluor 594 goat anti-rabbit IgG (Invitrogen), Alexa Fluor 594 goat 
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anti-mouse IgG (Invitrogen), Alexa Fluor 488 goat anti-mouse IgG (Invitrogen), and 
Alexa Fluor 350 goat anti-mouse IgG (Invitrogen). 
 
Microscopy and image analysis 
All IF and immuno-FISH images were collected using an inverted fluorescence 
microscope (Olympus, IX81) equipped with an UPlanSApo 40×/0.95 NA lens 
(Olympus), an UPlanSApo 100×/1.4 oil immersion lens (Olympus) and a high-resolution 
charge-coupled device camera (QImaging, FAST1394) at room temperature.  Photos 
were taken using either a 40× or 100× lens with immersion oil type-F (Olympus).  Image 
data were analyzed and presented using SlideBook 5.0 software (Intelligent Imaging 
Innovations, Inc.).  Images were cropped and scale bars were added using ImageJ 
software.  Relative intensities were analyzed using ImageJ software. 
The percentage of cells showing different foci or different localization pattern 
were quantified from approximately 50 to 200 positively transfected cells.  Means and 
standard deviations (SD) were calculated from at least three independent experiments.   
For Fig. 2.5, immunofluorescent images were analyzed using ImageJ software. 
The “Adjust Threshold” function of the ImageJ software was used to identify DAPI-
stained nuclei. The average BiFC signal intensity divided by nucleus area was measured 
using the “Analyze Particles” function of the software.  The BiFC signal intensity of 50 
cells transfected with vector and 50 cells transfected with HPV16 genome was measured 
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and divided by the nucleus area to get the values plotted.  This experiment was repeated 2 
times with similar results.   
 
Reverse Transcription (RT)-q-PCR 
Total RNA was isolated using a NucleoSpin RNA II Kit (Macherey-Nagel) 
following the manufacturer's instructions.  Reverse transcription was performed using a 
20 μl reaction mixture containing 350 ng of total RNA, oligo(dT) primer (Invitrogen), 
dNTP (Invitrogen), and M-MLV reverse transcriptase (Invitrogen), following the 
manufacturer's instructions.  Real time PCR was performed using a CFX96 real time 
PCR detection system (Bio-Rad) with IQ SYBR Green supermix (Bio-Rad).  The mRNA 
level of each gene was normalized to GAPDH mRNA level.  Primer sequences are shown 
in Table 4.1. 
 
Immunoblotting 
Cells were collected at 48 hours post transfection and washed once with PBS.  
The cell pellets were lysed in buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM 
EDTA, 0.1 mM EGTA, and 1 mM dithiothreitol (DTT), supplemented with protease 
inhibitors (Roche)). The cells were then incubated on ice for 10 minutes, and Nonidet P-
40 (NP-40) was added to a final concentration of 0.6%.  After vortexing and 
centrifugation at 5,000 rpm for 5 minutes, the nuclear pellet was resuspended in ice-cold 
buffer B (20 mM HEPES, pH 7.9, 0.4 M NaCl, 0.1 mM EDTA, 0.1 mM EGTA, and 1 
mM DTT, supplemented with protease inhibitors) and either incubated on ice for 15 
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minutes with vortexing or passed through a 20-gauge needle 10 times and mixed at 4°C 
for 1 hour.  The nuclear proteins were isolated by centrifugation at 14,000 rpm for 5-15 
minutes. The samples were then resolved by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE), transferred onto PVDF membrane, and immunoblotted 
with specific antibodies.  Antibodies employed in the Western blot analysis include: anti-
Brd4C (recognizing Brd4 aa1313-1362), anti-HPV16 E2 (Millipore), anti-Xpress 
(Invitrogen), anti-Actin (Chemicon), anti-glyceraldehyde-3-phosphate dehydrogenase 
(anti-GAPDH) (United States Biological), and anti-HA-HRP (Roche). Western blots 
were developed using ECL solution (PerkinElmer) and images were captured using a Fuji 
imaging system. 
 
Protein expression and purification 
To express rBrd4 in insect cells, either wild type or Ac-IIT-hBrd4 baculovirus 
was used to infect Sf9 cells.  Cells were lysed in IPP400 (20 mM HEPES, 0.4 M NaCl, 1 
mM EDTA, and protease inhibitors) by passing through a 20-gauge needle 15 times.  
Supernatant was isolated by centrifugation at 14,000 rpm for 30 minutes at 4°C, and the 
salt concentration was adjusted to 0.15 M.  Recombinant IIT-Brd4 was purified using 
IgG-Sepharose 6 Fast Flow (GE Healthcare) following the manufacturer’s instructions.  
The protein-bound Sepharose was washed with IPP150 (20 mM HEPES, 0.15 M NaCl, 1 
mM EDTA, 0.1% NP-40, and protease inhibitors) four times and IPP400 supplemented 
with 0.1% NP-40 twice.  rBrd4 was released from the Sepharose using TEV protease 
138 
	  
(Sigma) following the manufacturer’s instructions.  Expressed proteins were analyzed 
using SDS-PAGE, Coomassie brilliant blue staining, and/or immunoblotting. 
 
Immunoprecipitation 
 C33A cells were pelleted at 48 hours post transfection and resuspended in buffer 
A (10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, and 1 mM 
dithiothreitol (DTT) supplemented with protease inhibitors (Roche Applied Science)). 
The resuspended cells were incubated on ice for 10 minutes, and NP-40 was added to a 
final concentration of 0.6%. After vortexing and centrifugation at 5,000 rpm for 5 
minutes, the nuclear pellet was resuspended in ice-cold buffer B (20 mM HEPES (pH 
7.9), 0.4 mM NaCl, 1 mM EDTA, 1 mM EGTA, and 1 mM DTT, supplemented with 
protease inhibitors). To extract nuclear proteins, nuclei were passed through a 20-gauge 
needle ten times and extracted at 4°C for 1 hour. Nuclear proteins were isolated by 
centrifugation at 14,000 rpm for 15 minutes, diluted in buffer A, and pre-cleared with 3 
μg normal rabbit IgG (NRIgG) and 10 μl protein A sepharose 4 fast flow beads (GE 
Healthcore) at 4°C for 1 hour.  Pre-cleared lysates were then divided equally and 
immunoprecipitated with 1.8 μg of either NRIgG or Brd4NA antibody and 10 μl protein 
A beads (pre-blocked with 1% BSA in PBS at 4°C for 2 hour) at 4°C for 7 hours.  The 
beads were then washed 3 times with 60 mM KCl base buffer (20 mM Tris (pH 8.0), 
10% glycerol, 5 mM MgCl2, 60 mM KCl, and protease inhibitors (Roche Applied 
Science)) and eluted with sample buffer.  Input and IP samples were resolved by SDS-
PAGE and proteins were immunoblotted as described above. 
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In Fig. 4.4, C33A cells stably expressing Flag-HA-tagged E2TA were treated with 
500 nM JQ1(-) or JQ1(+) for 15 hours.  The cells were then pelleted and a nuclear 
extraction was performed as described above.  About 20 μg of nuclear protein were used 
as input for analysis of GAPDH protein level.  The remaining lysate was diluted in buffer 
A and incubated with 10 μl of pre-blocked (1% BSA in PBS for 1 hour at 4°C) anti-Flag 
M2 affinity gel beads (Sigma) overnight at 4°C.  The beads were then washed 3 times 
with 150 mM KCl base buffer (20 mM Tris (pH 8.0), 10% glycerol, 5 mM MgCl2, 0.1% 
Tween-20, 150 mM KCl, and protease inhibitors (Roche Applied Science)) and eluted 
with sample buffer.  Input and IP samples were resolved on a SDS-PAGE gel and 
proteins were immunoblotted as described above. 
 
Chromatin Immunoprecipitation (ChIP) 
For ChIP analysis, formaldehyde was added directly to cell culture media to a 
final concentration of 1%. Fixation was completed after incubation for 10 minutes at 
room temperature and stopped by adding glycine to a final concentration of 0.125 M. 
Cells were scraped, collected, centrifuged and swelled in cell lysis buffer (5 mM PIPES 
(pH 8.0), 85 mM KCl, 1% NP-40, 0.1 mM PMSF, and 1 μg/ml leupeptin, aprotinin and 
Pepstatin A). After 1 hour incubation on ice, nuclei were collected by centrifugation at 
4,000 rpm for 10 minutes at 4°C, resuspended in nuclei lysis buffer (50 mM Tris-HCl 
(pH 8.0), 1% SDS, 10 mM EDTA, 0.1 mM PMSF, and 1 μg/ml leupeptin, aprotinin and 
Pepstatin A) and incubated on ice for 10 minutes. Samples were sonicated on ice to an 
average DNA length of 500 bp and centrifuged at 14,000 rpm. The chromatin solution 
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was pre-cleared with Staph A cells (pre-blocked with 1 mg/ml sheared herring sperm 
DNA and 1 mg/ml BSA overnight at 4°C) for 15 minutes at 4°C. Chromatin from about 
107 cells was incubated with 5 μg of normal rabbit IgG (NRIgG, Millipore), an affinity-
purified rabbit polyclonal antibody Brd4NA (recognizes BRD4 aa 156-284) (207), or a 
Cdk9 antibody (Santa Cruz, sc-484). After rotating at 4°C overnight, chromatin and 
antibody complexes were immunoprecipitated by mixing with pre-blocked Staph A cells 
at 4°C for 15 minutes. Immunoprecipitates were centrifuged at 14,000 rpm for 3 minutes. 
The supernatant from the NRIgG antibody sample was used as total chromatin input. 
Staph A immuno-complexes were washed twice with dialysis buffer (50 mM Tris-HCl 
(pH 8.0), 2 mM EDTA, 0.2% Sarkosyl, 0.1 mM PMSF) and four times with ChIP wash 
buffer (100 mM Tris, pH 9.0, 500 mM LiCl, 1% NP-40, 1% deoxycholic acid, 0.1 mM 
PMSF). Immuno-complexes were eluted from the Staph A cells using elution buffer (50 
mM NaHCO3, 1% SDS). Crosslinking was reversed by adding NaCl to the eluted 
supernatants to a final concentration of 300 mM and incubating at 67°C overnight. RNA 
was removed by incubation with RNase A at 37°C for 30-60 minutes. DNA samples were 
purified using a PCR purification kit (Qiagen) and eluted in 50 μl elution buffer. Real-
time PCR was performed as described above using primers listed in Table 4.1. Two 
micro liters of immunoprecipitated DNA or total input chromatin diluted 1:50 were used 
as templates for the PCR reactions.  
 
Whole Genomic Extraction 
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Cells were treated with JQ1(-) or JQ1(+) for 15 hours prior to harvest.  
Trypsinized cells were washed with PBS and pelleted by centrifuging at 3000 rpm for 5 
minutes at 4°C.  The pellets were resuspended in lysis buffer (400 mM NaCl, 10 mM 
TrisCl (pH 7.4), 10 mM EDTA (pH 7.0), 0.2% SDS) and 45 μg of RNaseA (Roche) was 
added.  The lysates were then passed through a 22-gauge needle ten times and incubated 
at 37°C for 30 minutes.  Protein was then digested with 100 μg proteinase K (Roche) 
overnight at 37°C.  A phenol/chloroform extraction was then performed by adding 500 μl 
phenol/chloroform/isoamyl alcohol (25:24:1) (Sigma) to the samples then mixing for 5 
minutes at room temperature and microcentrifuging at 14,000 rpm for 5 minutes.  The 
aqueous supernatant was recovered and mixed with chloroform/isoamyl alcohol (24:1) 
(Sigma) for 5 minutes at room temperature.  After microcentrifugation at 14,000 rpm for 
5 minutes, the DNA in the aqueous supernatant was isolated and precipitated by adding 
2.5 volumes of isopropanol and 1/10 volume of 3M sodium acetate and incubating 
overnight at -20°C.  The DNA was pelleted by microcentrifuging at 14,000 rpm for 20 
minutes at 4°C.  The pellet was washed with 70% ethanol, microcentrifuged at 14,000 
rpm at room temperature, dried, and resuspended in water.  Viral episome levels were 
measured by qRT-PCR as described above using primers listed in Table 4.1.  The 
episomal DNA level was normalized to the GAPDH gene. 
 
Luciferase transactivation assay 
C33A cells were transfected using the calcium phosphate method and lysed in 
Reporter Lysis Buffer (Promega) at 48 hours post transfection.  Luciferase activities were 
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measured according to the manufacturer’s instructions (Luciferase Assay System; 
Promega).  In Figure 4.1, the luciferase activity was normalized to β-galactosidase 
activity measured using β-galactosidase Enzyme Assay System (Promega).  For Figures 
4.3 and 4.4, luciferase activities calculated from three independent experiments were 
presented and Western blotting analyses were performed to ensure that these luciferase 
activities resulted from similar amount of E2 proteins. 
 
Southern blot analysis and in vitro replication assay 
Episomal DNA for Southern blot analysis was isolated by the Hirt extraction 
method. Less than 1 million cells were re-suspended in 250 µl Buffer I (50 mM Tris and 
10 mM EDTA, supplemented with 50 µg/ml RNase A, pH 7.5), and frozen at -80°C for 
more than 20 minutes. Cells were mixed with 250 µl 1.2% SDS and incubated for 5 
minutes at room temperature. After incubation in 350 µl Buffer III (3 M CsCl, 1 M KAc, 
and 0.67 M HAc) for 10 minutes at room temperature, the samples were centrifuged at 
16,000 × g for 10 minutes. Supernatant was loaded onto a miniprep column (Qiagen) and 
washed twice with 10 mM Tris, 50 µM EDTA, 80 mM KAc, and 60% ethanol, pH 7.5. 
DNA was eluted with water or elution buffer (Qiagen). To linearize DNA and remove 
transfected DNA, 600-800 ng DNA from Hirt extraction was digested with XhoI/DpnI 
for 2 hours at 37°C. To detect transfected DNA, episomal DNA was extracted at 6 hours 
post transfection and digested with XhoI. Probes targeting the HPV16 E1 gene were 
labeled with [α-32P] dCTP (3000 Ci/mmol) using Prime-It II random primer labeling kit 
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(Agilent Technologies) following the manufacturer’s instructions. The hybridization was 
performed at 65°C overnight. 
For the in vitro replication assay, C33A cells were transfected with siRNA 
targeting Brd4 (siBrd4) or non-target siRNA.  At 36 hours post transfection, cells were 
re-transfected with HA-16E1 and pOZN-16E2 plasmids. After 48 hours, cells were 
swollen in 20 mM HEPES, 5 mM KCl, 1.5 mM MgCl2, 1 mM DTT, and 1 mM PMSF, 
pH8.0, and lysed with a Dounce homogenizer on ice. Supernatant was frozen at -80°C 
overnight. The in vitro replication reaction mixture contained: 40 mM creatine phosphate 
(pH 7.7, di-Tris salt), 7 mM MgCl2, 100 µg/ml creatine kinase, 0.5 mM DTT, 3.3 µM [α-
32P] dCTP (3000 Ci/mmol), 200 ng re-ligated HPV16 genome, and 150-200 µg cellular 
extracts, supplemented with 4 mM ATP, 200 µM each of CTP, UTP, GTP, and 80 µM 
each of dATP, dTTP, dGTP in a 50 µl volume. Mixtures were incubated for 2 hours at 
37°C. DNA was extracted with phenol, precipitated with ethanol, and linearized with 
BamHI. Purified recombinant Brd4 was added into the Brd4 rescue reactions. The band 
intensities of radiographs were analyzed using a Phosphorimager (Typhoon 9400; GE 
Healthcare). 
 
Flow cytometry 
Cells were detached from plates with 0.05% Trypsin-EDTA (GIBCO), re-
suspended/fixed with 70% ethanol, and stained with 25 µg/ml propidium iodide. RNA 
was digested with 100 µg/ml RNase A. Flow cytometry results were analyzed using 
FlowJo software. 
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